CUMULATIVE
SUPPLEMENT 7
JAN'98-JUL'98



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

1998

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

TL

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

Cumulative Supplement 7

JULY 1998

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

18TH EDITION

CUMULATIVE SUPPLEMENT 7
JULY 1998

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 18th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

IV

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 18th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 19th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA MERCK INC (ASTRA MERCK)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
ASTRA USA INC (ASTRA)	ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)
DUPONT RADIOPHARMACEUTICALS DIV (DUPONT)	DUPONT PHARMACEUTICALS COMPANY (DUPONT PHARMS)
FUJISAWA USA INC (FUJISAWA)	AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)

1.3 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novopharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.4 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Alcon's NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are available on Internet: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices.

These files may be accessed on the Internet's World Wide Web. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1997) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1997	MAR 1998	JUN 1998	SEP 1998
DRUG PRODUCTS LISTED	9624	9711	9768	
SINGLE SOURCE	2462 (25.6%)	2484 (25.6%)	2494 (25.6%)	
MULTISOURCE	7052 (73.3%)	7117 (73.3%)	7164 (73.3%)	
THERAPEUTICALLY EQUIVALENT	6673 (69.3%)	6746 (69.5%)	6790 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	379 (4.0%)	371 (3.8%)	374 (3.8%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	--	8	9	
NUMBER OF APPLICANTS	551	529	538	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ix

ACARBOSE

TABLET; ORAL
PRECOSE

	@	BAYER	25MG	N20482 004 MAY 29, 1997
			25MG	N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL,ACETAMINOPHEN AND CAFFEINE

> ADD >	AB	+	MIKART	500MG;50MG;40MG	N89451 001 MAY 23, 1988
> ADD >					
> ADD >	AB		WATSON LABS	500MG;50MG;40MG	N40267 001 JUL 30, 1998
> ADD >					

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		ROYCE LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA			300MG;30MG	N89998 001 DEC 28, 1994
AA			300MG;60MG	N89999 001 DEC 28, 1994
AA		WATSON LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA			300MG;30MG	N89998 001 DEC 28, 1994
AA			300MG;60MG	N89999 001 DEC 28, 1994

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051 001 AUG 28, 1992
AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001 MAR 13, 1998

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		MALLINCKRODT	500MG;7.5MG	N40201 001 FEB 27, 1998

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG;10MG	N40201 002
AA	ROYCE LABS	500MG;2.5MG	
AA		500MG;5MG	
AA		500MG;7.5MG	
AA		650MG;7.5MG	
AA		650MG;10MG	
AA		750MG;7.5MG	
AA	WATSON LABS	500MG;2.5MG	MAR 04, 1996
AA		500MG;5MG	N40122 001 MAR 04, 1996
AA		500MG;7.5MG	N40123 004 MAR 04, 1996
AA		650MG;7.5MG	N40123 001 MAR 04, 1996
AA		650MG;10MG	N40123 002 MAR 04, 1996
AA		750MG;7.5MG	N40122 002 MAR 04, 1996

ACETAMINOPHEN; OXYCODONE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	HALSEY	500MG;5MG	N40219 001 JAN 22, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	ROYCE LABS	500MG;5MG	N40234 001 OCT 30, 1997
AA	WATSON LABS	500MG;5MG	N40234 001 OCT 30, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

AA	DURAMED	325MG;5MG	N40272 001 JUN 30, 1998
AA	ROXCR LABS	325MG;5MG	N40171 001 OCT 30, 1997
AA	WATSON LABS	325MG;5MG	N40171 001 OCT 30, 1997

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	ROXCR LABS	650MG;65MG	N40139 001 DEC 16, 1996
AA	WATSON LABS	650MG;65MG	N40139 001 DEC 16, 1996

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	B BRAUN	250MG/100ML	N18161 001
AT	MCGAW	250MG/100ML	N18161 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	CHELSEA LABS	200MG	N75101 001 APR 15, 1998
AB	GENPHARM	200MG	N74977 001 APR 13, 1998

TABLET; ORAL
ACYCLOVIR

AB	COPLEY PHARM	400MG	N75021 001 MAR 18, 1998
AB		800MG	N75021 002 MAR 18, 1998
AB	GENPHARM	400MG	N74976 001 APR 13, 1998
AB		800MG	N74976 002 APR 13, 1998

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR

*	NOVOPHARM	200MG	N74556 001 APR 22, 1997
◉		200MG	N74556 001 APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AESGEN	EQ 500MG BASE/VIAL	N75015 001 APR 30, 1998
AP	APOTHECON	EQ 500MG BASE/VIAL	N74897 001 FEB 27, 1998
AP		EQ 1GM BASE/VIAL	N74897 002 FEB 27, 1998
>DLT> AP	FUJISAWA	EQ 500MG BASE/VIAL	N74930 001 MAY 13, 1998
>DLT> >ADD> +		EQ 50MG BASE/ML	N74930 001 MAY 13, 1998

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD

+	FUJISAWA HLTHCARE	3MG/ML	N19937 002 OCT 30, 1989
*	MEDCO RES	3MG/ML	N19937 002 OCT 30, 1989

ADENOSCAN

+	FUJISAWA HLTHCARE	3MG/ML	N20059 001 MAY 18, 1995
*	MEDCO RES	3MG/ML	N20059 001 MAY 18, 1995

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN	BAUSCH AND LOMB	EQ 0.5% BASE	N75050 001 JUN 18, 1998
AN	HI TECH PHARMA	EQ 0.5% BASE	N74543 001 JAN 15, 1998

ALBUTEROL SULFATE

SYRUP; ORAL
ALBUTEROL SULFATE

AA		HI TECH PHARMA	EQ 2MG BASE/5ML	N74749 001 JAN 30, 1998
AA		NOVA	EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994
	@		EQ 2MG BASE/5ML	N74302 001 SEP 30, 1994

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB		GENEVA PHARMS	2MG	N74909 001 MAR 25, 1998
AB		ROYCE LABS	0.25MG	N74479 001 JAN 21, 1997
AB			0.5MG	N74479 002 JAN 21, 1997
AB			1MG	N74479 003 JAN 21, 1997
AB		WATSON LABS	0.25MG	N74479 001 JAN 21, 1997
AB			0.5MG	N74479 002 JAN 21, 1997
AB			1MG	N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL

AP		BEDFORD	0.5MG/ML	N74815 001 JAN 20, 1998

PROSTIN VR PEDIATRIC

AP	+	PHARMACIA AND UPJOHN	0.5MG/ML	N18484 001
	*		0.5MG/ML	N18484 001

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
SYMMETREL

AA	*	ENDO PHARMS	50MG/5ML	N16023 002
AA	+	ENDO PHARMS	50MG/5ML	N16023 002

AMANTADINE HYDROCHLORIDE

TABLET; ORAL
SYMMETREL

	@	ENDO PHARMS	100MG	N18101 001
	+		100MG	N18101 001

AMCINONIDE

OINTMENT; TOPICAL
CYCLOCORT

	*	LEDERLE	0.1%	N18498 001
	+	WYETH AYERST	0.1%	N18498 001

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB		ROYCE LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991
AB		WATSON LABS	EQ 5MG ANHYDROUS;50MG	N73334 001 JUL 19, 1991

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
CORDARONE

AB	+	WYETH AYERST	200MG	N18972 001 DEC 24, 1985

PACERONE

AB		UPSHER SMITH	200MG	N75135 001 APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB		ROYCE LABS	2MG;[illegible]
AB			4MG;[illegible]
AB			2MG;[illegible]
AB			4MG;[illegible]

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

AB	WATSON LABS	10MG;2MG	N73007 001	OCT 17, 1991
AB		10MG;4MG	N73009 001	OCT 17, 1991
AB		25MG;2MG	N73008 001	OCT 17, 1991
AB		25MG;4MG	N73010 001	OCT 17, 1991

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
AMMONIUM CHLORIDE 2.14%

@	B BRAUN	40MEQ/100ML	N85734 001
@	[illegible]	[illegible]	[illegible]

AMOXICILLIN

TABLET; ORAL
AMOXIL

>ADD>	+	SMITHKLINE BEECHAM	500MG	N50754 002 JUL 10, 1998
>ADD>	+		875MG	N50754 001 JUL 10, 1998

AMRINONE LACTATE

INJECTABLE; INJECTION
INOCOR

		SANOFI	EQ 5MG BASE/ML	[illegible]
	+		EQ 5MG BASE/ML	N18700 001 JUL 31, 1984

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	*	GENSIA	0.05MG/ML	[illegible]

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
GENESA

	+	GENSIA AUTOMEDICS	0.05MG/ML	N20420 001 SEP 12, 1997

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

AB		PAR PHARM	385MG;30MG;25MG	N75141 001 MAY 29, 1998

ORPHENGESIC FORTE

AB		PAR PHARM	770MG;60MG;50MG	N75141 002 MAY 29, 1998

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

>ADD> AA		HALSEY	325MG;4.5MG;0.38MG	N40260 001 JUL 17, 1998
>ADD> AA		WATSON LABS	325MG;4.5MG;0.38MG	N40255 001 FEB 27, 1998

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB		MARTEC	50MG;25MG	N74404 001 MAY 14, 1998
AB			100MG;25MG	N74404 002 MAY 14, 1998

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

		PARKE DAVIS	EQ 10MG BASE	[illegible]
			EQ 20MG BASE	
	*		EQ 40MG BASE	

ATORVASTATIN CALCIUM

TABLET; ORAL
LIPITOR

		WARNER LAMBERT EXPOR	EQ 10MG BASE		N20702 001 DEC 17, 1996
			EQ 20MG BASE		N20702 002 DEC 17, 1996
	+		EQ 40MG BASE		N20702 003 DEC 17, 1996

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

> ADD >	AP	MARSAM	10MG/ML		M74945 001 JUL 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

> ADD >	AP	MARSAM	10MG/ML		M74944 001 JUL 28, 1998

BACITRACIN

POWDER; FOR RX COMPOUNDING
BACITRACIN

		PADDOCK	5,000,000 UNITS/BOT		[illegible] JUL 27, 1983
	@		5,000,000 UNITS/BOT		N62456 001 JUL 27, 1983

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOSPORIN

AT	*	GLAXO WELLCOME	[illegible]		[illegible]
AT	+	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50417 001

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		ADV. [illegible]	[illegible]		[illegible] JAN 30, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	500 UNITS/GM; 10,000 UNITS/GM		M64028 001 JAN 30, 1995

POLYSPORIN

AT	*	GLAXO WELLCOME	[illegible]		[illegible]
AT	+	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM		M61229 001

BACLOFEN

TABLET; ORAL
BACLOFEN

AB		ROXANE LABS	10MG		[illegible] JAN 28, 1994
AB			20MG		[illegible] JAN 28, 1994
AB		WATSON LABS	10MG		M73092 001 JAN 28, 1994
AB			20MG		M73093 001 JAN 28, 1994

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

		JANNSEN PH	300MG		[illegible] NOV 28, 1990
	*		400MG		[illegible] DEC 28, 1990
	+		300MG		N19002 002 DEC 28, 1990
	@		400MG		N19002 003 DEC 28, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

AN		CLAY PARK	[illegible]		[illegible] JUN 10, 1998

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
◉ CLAY PARK — EQ 0.1% BASE — N70053 001 — JUN 10, 1986

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT
\+ ALCON — 1% — N20816 001 — APR 01, 1998

BROMOCRIPTINE MESYLATE

TABLET; ORAL
BROMOCRIPTINE MESYLATE
AB LEK PHARM — EQ 2.5MG BASE — N74631 001 — JAN 13, 1998

PARLODEL
AB \+ NOVARTIS — EQ 2.5MG BASE — N17962 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN — 37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML — N19864 001 — JUN 10, 1993
MCGAW — 37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML — N19864 001 — JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN — 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML — N19867 001 — DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW — 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML — N19867 001 — DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER
AP B BRAUN — 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML — N18256 001
AP — 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML — N20000 001 — APR 17, 1992
AP MCGAW — 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML — N18256 001
AP — 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML — N20000 001 — APR 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER
◉ B BRAUN — 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML — N17510 001
◉ MCGAW — 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML — N17510 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
B BRAUN — 35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML — N19718 001 — SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
NCGAN 35MG/100ML;10MG/100ML;74MG/100ML; 68MG/100ML;500MG/100ML; 74MG/100ML N19718 001 SEP 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER
ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

SOLUTION; PERFUSION/CARDIAC
PLEGISOL IN PLASTIC CONTAINER
+ ABBOTT 17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML N18608 001 FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 33MG/100ML;30MG/100ML; 860MG/100ML N18721 001 NOV 09, 1982
AP 33MG/100ML;30MG/100ML; 860MG/100ML N20002 001 APR 17, 1992 >ADD>
AP NCGAN [illegible] >ADD>
[illegible] >ADD>
AP [illegible] >ADD>

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 33MG/100ML;30MG/100ML; 860MG/100ML N18156 001 >DLT>

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER
AT NCGAN [illegible] N18156 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER
AP B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N19632 001 FEB 29, 1988
● 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18023 001
AP NCGAN [illegible]
●

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER
AT B BRAUN 20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML N18681 001 DEC 27, 1982
AT NCGAN [illegible]

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
ASTRA HASSLE 4MG [illegible] JUN 04, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

>DLT>	[redacted]	[redacted]	[redacted]	
>DLT>		[redacted]		
>DLT>		[redacted]		
>DLT>		[redacted]		
>DLT>	*	[redacted]		
>DLT>				
>ADD>		ASTRA PHARMS	4MG	N20838 001 JUN 04, 1998
>ADD>				
>ADD>			8MG	N20838 002 JUN 04, 1998
>ADD>				
>ADD>			16MG	N20838 003 JUN 04, 1998
>ADD>				
>ADD>	+		32MG	N20838 004 JUN 04, 1998
>ADD>				

CAPECITABINE

TABLET; ORAL
XELODA

		ROCHE	150MG	N20896 001 APR 30, 1998
	+		500MG	N20896 002 APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

[redacted]		[redacted]	[redacted]	[redacted]
[redacted]			[redacted]	
[redacted]			[redacted]	
[redacted]			[redacted]	
AB		WATSON LABS	12.5MG	[redacted] FEB 13, 1996
AB			25MG	N74451 002 FEB 13, 1996
AB			50MG	N74451 003 FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB		WATSON LABS	100MG	N74451 004 FEB 13, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/15

AB		BRISTOL MYERS SQUIBB	25MG;15MG	N18709 001 OCT 12, 1984
[redacted]		[redacted]	[redacted]	[redacted]

CAPOZIDE 25/25

AB	+	BRISTOL MYERS SQUIBB	25MG;25MG	N18709 002 OCT 12, 1984
[redacted]	*	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/15

AB	+	BRISTOL MYERS SQUIBB	50MG;15MG	N18709 004 OCT 12, 1984
[redacted]	*	[redacted]	[redacted]	[redacted]

CAPOZIDE 50/25

AB		BRISTOL MYERS SQUIBB	50MG;25MG	N18709 003 OCT 12, 1984
[redacted]		[redacted]	[redacted]	[redacted]

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		ZENITH GOLDLINE	25MG;15MG	N75055 001 JUN 18, 1998
AB			25MG;25MG	N75055 002 JUN 18, 1998
AB			50MG;15MG	N75055 004 JUN 18, 1998
AB			50MG;25MG	N75055 003 JUN 18, 1998

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

[redacted]	*	[redacted]	[redacted]	[redacted]

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

	*	[redacted]	300MG	[redacted]
	+	SHIRE	200MG	N20712 001 SEP 30, 1997
	+		300MG	N20712 002 SEP 30, 1997

CARBIDOPA

TABLET; ORAL
LODOSYN

> DLT >	*	[redacted]	25MG	[redacted]
> ADD >	+	DUPONT PHARMS	25MG	N17830 001

CARBIDOPA; LEVODOPA

TABLET; ORAL
SINEMET

> DLT >	AB	[redacted]	[redacted]	[redacted]
> DLT >	AB		[redacted]	[redacted]
> DLT >	AB	*	[redacted]	[redacted]
> ADD >	AB	DUPONT PHARMS	10MG;100MG	N17555 001
> ADD >	AB		25MG;100MG	N17555 003
> ADD >	AB	+	25MG;250MG	N17555 002

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

> DLT >		[redacted]	[redacted]	[redacted]
> DLT >				DEC 24, 1992
> DLT >	*		[redacted]	[redacted]
> DLT >				MAY 30, 1991
> ADD >		DUPONT PHARMS	25MG;100MG	N19856 002
> ADD >				DEC 24, 1992
> ADD >	+		50MG;200MG	N19856 001
> ADD >				MAY 30, 1991

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA		[redacted]	[redacted]	[redacted]

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA		WATSON LABS	350MG	N40152 001 DEC 03, 1996

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB		MARSAM	EQ 125MG BASE/5ML	N64204 001 FEB 18, 1998
AB			EQ 187MG BASE/5ML	N64205 001 FEB 18, 1998
AB			EQ 250MG BASE/5ML	N64206 001 FEB 18, 1998
AB			EQ 375MG BASE/5ML	N64207 001 FEB 18, 1998

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		FUJISAWA	EQ 10GM BASE/VIAL	N64170 001 MAR 18, 1998
AP			EQ 20GM BASE/VIAL	N64170 002 MAR 18, 1998

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	*	[redacted]	[redacted]	[redacted]
	*		[redacted]	[redacted]
	*		[redacted]	[redacted]
			[redacted]	[redacted]
	+	FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	SEP 15, 1983
	+		EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX
+ FUJISAWA HLTHCARE — EQ 2GM BASE/VIAL — N50560 003 SEP 15, 1983
EQ 10GM BASE/VIAL — N50560 005 MAR 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER
[redacted] — [redacted] — [redacted]
● FUJISAWA HLTHCARE — EQ 40MG BASE/ML — N50589 002 OCT 03, 1984

CEFIZOX IN PLASTIC CONTAINER
[redacted] — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]
+ FUJISAWA HLTHCARE — EQ 20MG BASE/ML — N50589 003 APR 13, 1995
+ EQ 40MG BASE/ML — N50589 004 APR 13, 1995

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME
AB ASTRA PHARMS — EQ 750MG BASE/VIAL — N64192 002 APR 16, 1998
AP EQ 1.5GM BASE/VIAL — N64192 001 APR 16, 1998
AP EQ 7.5GM BASE/VIAL — N64191 001 APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN
AB ZENITH GOLDLINE — EQ 250MG BASE — N61969 001
AB EQ 500MG BASE — N61969 002
[redacted] ZENITH LABS — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]

POWDER FOR RECONSTITUTION; ORAL
KEFLEX
[redacted] LILLY — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
KEFLEX
● LILLY — EQ 100MG BASE/ML — N50406 003
+ EQ 100MG BASE/ML — N62117 001

CHLORAMPHENICOL

CAPSULE; ORAL
CHLOROMYCETIN
[redacted] [redacted] PARKE DAVIS — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]
[redacted] — [redacted] — [redacted]
AB + PARKEDALE — 250MG — N60591 002
50MG — N60591 001
+ 100MG — N60591 003

OINTMENT; OPHTHALMIC
CHLOROMYCETIN
[redacted] [redacted] PARKE DAVIS — [redacted] — [redacted]
AT + PARKEDALE — 1% — N50156 001

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN
[redacted] PARKE DAVIS — [redacted] — [redacted]
+ PARKEDALE — 25MG/VIAL — N50143 001

SOLUTION/DROPS; OPHTHALMIC
OPHTHOCHLOR
[redacted] [redacted] PARKE DAVIS — [redacted] — [redacted]
AT PARKEDALE — 0.5% — N61220 001

SOLUTION/DROPS; OTIC
CHLOROMYCETIN
[redacted] PARKE DAVIS — [redacted] — [redacted]
+ PARKEDALE — 0.5% — N50205 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

POWDER FOR RECONSTITUTION; OPHTHALMIC
CHLOROMYCETIN HYDROCORTISONE
[redacted] PARKE DAVIS — [redacted] — [redacted]
+ PARKEDALE — 12.5MG/VIAL;25MG/VIAL — N50202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
[redacted] 10MG/GM;5MG/GM; 10,000 UNITS/GM [redacted]
● PARKEDALE 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLOROMYCETIN
[redacted]
AP ✦ PARKEDALE EQ 1GM BASE/VIAL N50155 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS
✦ ICN 5MG N85482 001
● 10MG N85481 001
● 25MG N85488 001
[redacted]

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
LIBRIUM
AB ICN 5MG N85461 001
AB 10MG N85472 001
AB ✦ 25MG N85475 001
[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX
[redacted] AUG 13, 1986

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX
AT ✦ ZILA 0.12% N19028 001 AUG 13, 1986

TABLET; DENTAL
PERIOCHIP
✦ PERIO PRODS (IS) 2.5MG N20774 001 MAY 15, 1998

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
[redacted]
● 25MG/ML N89563 001 APR 15, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
[redacted]
AA WATSON LABS 500MG N81040 001 AUG 22, 1989

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE
AB NOVOPHARM EQ 4GM RESIN/PACKET N74347 001 MAY 28, 1998
AB EQ 4GM RESIN/SCOOPFUL N74347 002 MAY 28, 1998

CHOLESTYRAMINE LIGHT
AB NOVOPHARM EQ 4GM RESIN/PACKET N74348 001 MAY 28, 1998
AB EQ 4GM RESIN/SCOOPFUL N74348 002 MAY 28, 1998

LOCHOLEST
AB EON EQ 4GM RESIN/PACKET N74561 001 AUG 15, 1996

CHOLESTYRAMINE

POWDER; ORAL

	LOCHOLEST				
AB	EON	EQ 4GM RESIN/SCOOPFUL	N74561 002	> ADD >	
			AUG 15, 1996	> ADD >	
	@	EQ 4GM RESIN/PACKET	N74561 001		
			AUG 15, 1996		
	@	EQ 4GM RESIN/SCOOPFUL	N74561 002		
			AUG 15, 1996		
	LOCHOLEST LIGHT				
AB	EON	EQ 4GM RESIN/PACKET	N74562 001		
			AUG 15, 1996		
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002		
			AUG 15, 1996		
	@	EQ 4GM RESIN/PACKET	N74562 001		
			AUG 15, 1996		
	@	EQ 4GM RESIN/SCOOPFUL	N74562 002		
			AUG 15, 1996		

CIMETIDINE

SOLUTION; ORAL

	CIMETIDINE HCL				
AA	DURAMED	300MG/5ML	N75110 001		
			JUN 18, 1998		

TABLET; ORAL

	CIMETIDINE			> DLT >	
AB	BAKER NORTON	200MG	N74424 001	> DLT >	
			JUL 28, 1995		
AB		300MG	N74424 002		
			JUL 28, 1995	> ADD >	
AB		400MG	N74424 003	> ADD >	
			JUL 28, 1995		
AB		800MG	N74424 004		
			JUL 28, 1995	> ADD >	
AB	ZENITH LABS	200MG	N74424 001		
			JUL 28, 1995	> ADD >	
AB		300MG	N74424 002	> ADD >	
			JUL 28, 1995	> ADD >	
AB		400MG	N74424 003	> ADD >	
			JUL 28, 1995	> ADD >	
AB		800MG	N74424 004	> ADD >	
			JUL 28, 1995	> ADD >	
				> ADD >	

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

	CIMETIDINE HCL				
AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001		
			JUL 09, 1998		

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

	CILOXAN				
	+ ALCON	EQ 0.3% BASE	N20369 001		
			MAR 30, 1998		

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

	CIPRO HC				
	+ BAYER	EQ 0.2% BASE;1%	N20805 001		
			FEB 10, 1998		

CISAPRIDE MONOHYDRATE

TABLET; ORAL

	PROPULSID QUICKSOLV				
	JANSSEN	EQ 20MG BASE	N20767 001		
			NOV 07, 1997		

TABLET, ORALLY DISINTEGRATING; ORAL

	PROPULSID QUICKSOLV				
	+ JANSSEN	EQ 20MG BASE	N20767 001		
			NOV 07, 1997		

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

	CELEXA				
	FOREST LABS	EQ 20MG BASE	N20822 002		
			JUL 17, 1998		
		EQ 40MG BASE	N20822 003		
			JUL 17, 1998		
	+	EQ 60MG BASE	N20822 004		
			JUL 17, 1998		

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	MORTON GROVE	EQ 0.5MG BASE/5ML	N74863 001 MAR 13, 1998

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN 3

+	PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002 MAR 02, 1998

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	[illegible]	[illegible]	[illegible]
●		EQ 150MG BASE/ML	N62913 001 OCT 20, 1988

SOLUTION; TOPICAL
CLEOCIN T

AP	[illegible]	[illegible]	[illegible]
●		EQ 1% BASE	N62363 001 FEB 08, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	MYLAN	25MG	N74947 001 APR 30, 1998
AB		50MG	N74947 002 APR 30, 1998
AB		75MG	N74947 003 APR 30, 1998

CLONAZEPAM

[illegible]

*	ROCHE	[illegible]	[illegible] [illegible]

CLONAZEPAM

[illegible]

*	[illegible]	[illegible]	[illegible]
		[illegible]	[illegible]
		[illegible]	[illegible]
*		[illegible]	[illegible]

TABLET, ORALLY DISINTEGRATING; ORAL
KLONOPIN RAPIDLY DISINTEGRATING

+	ROCHE	0.125MG	N20813 001 DEC 23, 1997
		0.25MG	N20813 002 DEC 23, 1997
		0.5MG	N20813 003 DEC 23, 1997
		1MG	N20813 004 DEC 23, 1997
+		2MG	N20813 005 DEC 23, 1997

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M

*	[illegible]	[illegible]	[illegible]
+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH

*	[illegible]	[illegible]	[illegible]
*		[illegible]	[illegible]
●	PARKEDALE	25 UNITS/VIAL	N08317 002
●		40 UNITS/VIAL	N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	CROLOM				
AT	BAUSCH AND LOMB	4%	N74443 001		
			JAN 30, 1995		
	[redacted]	[redacted]	[redacted]		
	CROMOLYN SODIUM				
AT	ADV REMEDIES	4%	N74706 001		
			APR 29, 1998		
	OPTICROM				
AT	+ ALLERGAN	4%	N18155 001		
			OCT 03, 1984		
	# [redacted]	[redacted]	[redacted]		

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL				
AB	[redacted]	[redacted]	[redacted]		
AB	WATSON LABS	10MG	N74436 001		
			NOV 30, 1994		

DACTINOMYCIN

INJECTABLE; INJECTION

	COSMEGEN				
	+ MERCK	0.5MG/VIAL	N50682 001		
	# [redacted]	[redacted]	[redacted]		

DALTEPARIN SODIUM

INJECTABLE; INJECTION

	FRAGMIN				
	+ [redacted]	[redacted]	[redacted]	>ADD<	
			JAN 30, 1998	>ADD<	
	+	10,000 IU/ML	N20287 004	>ADD<	
			JAN 30, 1998		
				>ADD<	
				>ADD<	

DANAZOL

CAPSULE; ORAL

	DANAZOL				
AB	BARR	50MG	N74582 003		
			MAY 29, 1998		
AB		100MG	N74582 002		
			MAY 29, 1998		
	DANOCRINE				
AB	SANOFI	50MG	N17557 003		
AB		100MG	N17557 004		

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	CERUBIDINE				
	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001	>ADD<	
			FEB 03, 1995	>ADD<	
	DAUNORUBICIN HCL				
	# [redacted]	[redacted]	[redacted]	>DLT<	
			[redacted]	>DLT<	
	DAUNORUBICIN HCL PRESERVATIVE FREE				
AP	+ BEDFORD	EQ 20MG BASE/VIAL	N50731 001		
			JAN 30, 1998		
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001		
			JUN 23, 1998		

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

	MIRCETTE				
	+ ORGANON	0.15MG;0.02MG	N20713 001		
			APR 22, 1998		

DESOXIMETASONE

GEL; TOPICAL

	DESOXIMETASONE				
AB	TARO	0.05%	N74904 001		
			JUL 14, 1998		
	TOPICORT				
AB	+ HOECHST MARION RSSL	0.05%	N18586 001		
			MAR 29, 1982		

OINTMENT; TOPICAL

	DESOXIMETASONE				
AB	ALTANA	0.25%	N73440 001		
			APR 01, 1998		

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL, METERED; INHALATION
DEXACORT
+ MEDEVA — EQ 0.1MG PHOSPHATE/INH — N13413 001
@ — EQ 0.1MG PHOSPHATE/INH — N13413 001

DISC; NASAL
DEXACORT
+ MEDEVA — EQ 0.1MG PHOSPHATE/INH — N14242 001
@ — EQ 0.1MG PHOSPHATE/INH — N14242 001

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXEDRINE
> DLT > AA + SMITHKLINE BEECHAM — 5MG — N84933 001
> ADD > AA — 5MG — N84935 001
DEXTROSTAT
> DLT > AA SHIRE RICHWOOD — 5MG — N84051 001
> ADD > AA + — 5MG — N84051 001

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
AP B BRAUN — 10GM/100ML — N18046 001
AP MCGAW — 10GM/100ML — N18046 001
DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN — 5GM/100ML — N16730 001
AP — 50MG/ML — N16730 002
AP MCGAW — 5GM/100ML — N16730 001
AP — 50MG/ML — N16730 002

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN — 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML — N19873 001 JUN 10, 1993
MCGAW — 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML — N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN — 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML — N19844 001 JUN 10, 1993
MCGAW — 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML — N19844 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN — 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML — N19843 001 AUG 09, 1993
AP MCGAW — 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML — N19843 001 AUG 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN — 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML — N18274 001
AP MCGAW — 5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML — N18274 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN — 5GM/100ML;75MG/100ML — N18744 001 NOV 09, 1982
AP MCGAW — 5GM/100ML;75MG/100ML — N18744 001 NOV 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993	
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

●	B BRAUN	10GM/100ML;900MG/100ML	N18047 001
●	MCGAW	10GM/100ML;900MG/100ML	N18047 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

●	B BRAUN	5GM/100ML;900MG/100ML	N18026 001
●	MCGAW	5GM/100ML;900MG/100ML	N18026 001

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP		MARSAN	5MG/ML	N72371 001 JAN 29, 1993
	●		5MG/ML	N72371 001 JAN 29, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB		ALCON	0.1% †	N20809 001 MAY 04, 1998

VOLTAREN

AB	◆	CIBA	0.1%	N20037 001 MAR 28, 1991

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL
DICYCLOMINE HCL

AB		MARR	20MG	N84600 001 JUL 29, 1985
	●		20MG	N84600 001 JUL 29, 1985

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB		ALTANA	0.05%	N75187 001 MAR 30, 1998

PSORCON

AB	◆	DERMIK LABS	0.05%	N20205 001 NOV 20, 1992
RX	◆		0.05%	N20205 001 NOV 20, 1992

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARTIA XT

●	ANDRX PHARMS	120MG	N74752 002 JUL 09, 1998
●		180MG	N74752 001 JUL 09, 1998
●		240MG	N74752 003 JUL 09, 1998
●		300MG	N74752 004 JUL 09, 1998

DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002 MAR 18, 1998
AB2		180MG	N75124 003 MAR 18, 1998
AB2		240MG	N75124 001 MAR 18, 1998

TIAZAC

BC		BIOVAIL	120MG	N20401 001 SEP 11, 1995
BC	◆		120MG	N20401 001 SEP 11, 1995
BC			180MG	N20401 002 SEP 11, 1995

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

† SEE SECTION 1.4 OF INTRODUCTION

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TIAZAC

BC	+	BIOVAIL	180MG	N20401 002 SEP 11, 1995	
BC			240MG	N20401 003 SEP 11, 1995	> ADD >
BC	+		240MG		
BC			300MG	N20401 004 SEP 11, 1995	> ADD >
BC	+		300MG		
			360MG	N20401 005 SEP 11, 1995	> ADD >
	+		360MG		

INJECTABLE; INJECTION

DILTIAZEM HCL

AP	ABBOTT	5MG/ML	N74941 001 APR 15, 1998
AP	TAYLOR PHARMA	5MG/ML	N75086 001 APR 09, 1998

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

> DLT >	#	[redacted]	10MG	N20411 001 MAR 30, 1995
> DLT >	+	FOREST LABS	10MG	N20411 001 MAR 30, 1995
> ADD >				
> ADD >				

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HCL

AA	[redacted]	[redacted]	N83237 001 JAN 25, 1982
	@	12.5MG/5ML	N83237 001 JAN 25, 1982

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	BEOFORD	5MG/ML	N74939 001 APR 13, 1998

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@	KV PHARM	EQ 100MG BASE	N71929 001 AUG 19, 1988

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001 JUN 25, 1998
AP	MARSAM	EQ 12.5MG BASE/ML	N74279 001 FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001 MAR 31, 1998

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT

+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	
AB		[redacted]	
AB	WATSON LABS	EQ 10MG BASE	MAR 29, 1991

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIN HCL

AB	WATSON LABS	EQ 25MG BASE	N72986 001 MAR 29, 1991
AB		EQ 50MG BASE	N72987 001 MAR 29, 1991

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
RUBEX

AP	BRISTOL MYERS	[illegible]	[illegible]
AP		[illegible]	[illegible]
		[illegible]	[illegible]
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	[illegible] APR 13, 1989
AP		50MG/VIAL	N62926 002 APR 13, 1989
		100MG/VIAL	N62926 003 APR 13, 1989

DYPHYLLINE

INJECTABLE; INJECTION
[illegible]

*	TEVA	[illegible]	[illegible]
@		250MG/ML	N09088 001

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE

AP	ABBOTT	10MG/ML	N40131 001 FEB 24, 1998

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL
ENKAID

	BRISTOL MYERS SQUIBB	25MG	[illegible] DEC 24, 1986

ENCAINIDE HYDROCHLORIDE

[illegible]

	[illegible]	[illegible]	[illegible]
@		25MG	N18981 002 DEC 24, 1986
@		35MG	N18981 003 DEC 24, 1986

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

+	RHONE POULENC RORER	40MG/0.4ML	N20164 002 JAN 30, 1998
+		60MG/0.6ML	N20164 003 MAR 27, 1998
+		80MG/0.8ML	N20164 004 MAR 27, 1998
+		100MG/ML	N20164 005 MAR 27, 1998

EPTIFIBATIDE

INJECTABLE; INJECTION
INTEGRILIN

+	COR	75MG/100ML	N20718 002 MAY 18, 1998
+		2MG/ML	N20718 001 MAY 18, 1998

ERYTHROMYCIN

OINTMENT; OPHTHALMIC
ERYTHROMYCIN

AT	[illegible]	[illegible]	[illegible] JUL 18, 1996
AT	AKORN	0.5%	N64030 001 JUL 18, 1996

OINTMENT; TOPICAL
AKNE-MYCIN

*	[illegible]	2%	[illegible] JAN 10, 1983

ERYTHROMYCIN

OINTMENT; TOPICAL

AKNE-MYCIN

+	EM INDS	2%	N50584 001	JAN 10, 1985

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

AB	[redacted]	[redacted]	[redacted]	
AB		333MG	N60272 002	

ERY-TAB

AB	[redacted]	[redacted]	[redacted]	
AB		250MG	N62298 001	
AB	+	[redacted]	[redacted]	
AB		[redacted]	[redacted]	
AB	+	333MG	N62298 003	MAR 29, 1982
AB		[redacted]	[redacted]	
AB	+	500MG	N62298 002	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+	BAXTER PHARM PROD	10MG/ML	N19386 001	AUG 15, 1988
[redacted]		100MG/ML	N19386 003	DEC 31, 1986
+		250MG/ML	N19386 002	
[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >
> DLT >

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB	[redacted]	[redacted]	[redacted]	
AB		[redacted]	[redacted]	
AB	WATSON LABS	1MG	N74818 001	AUG 19, 1997
AB		2MG	N74818 002	AUG 19, 1997

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001	DEC 20, 1996
BX		0.075MG/24HR	N20655 002	DEC 20, 1996
BX		0.1MG/24HR	N20655 003	
[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	

CLIMARA

BX	+ BERLEX	0.075MG/24HR	N20375 003	MAR 23, 1998

TABLET; ORAL

ESTRADIOL

AB	ENDEAVOR	0.5MG	N40138 001	JAN 30, 1998
AB		1MG	N40138 002	JAN 30, 1998
AB		2MG	N40138 003	JAN 30, 1998

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

[redacted]	[redacted]	[redacted]	[redacted]	

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL
[redacted] [redacted] [redacted] [redacted]
● 1MG/ML N85470 001
● 3MG/ML N85470 002

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
AO + BRISTOL MYERS SQUIBB 20MG/ML N09402 004
AO + 40MG/ML N09402 003
+ 10MG/ML N09402 002
[redacted] [redacted] [redacted] [redacted]

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELADUMONE
> ADD > ● BRISTOL MYERS SQUIBB 4MG/ML;90MG/ML N09545 001
> DLT > ● [redacted] [redacted] [redacted]
DELADUMONE OB
> ADD > ● BRISTOL MYERS SQUIBB 8MG/ML;180MG/ML N09545 002
> DLT > ● [redacted] [redacted] [redacted]

ESTRONE

INJECTABLE; INJECTION
THEELIN
● [redacted] [redacted] [redacted]
● [redacted] [redacted] [redacted]
● [redacted] [redacted] [redacted]
● PARKEDALE 1MG/ML N03977 001
● 2MG/ML N03977 002
● 5MG/ML N03977 003

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
> ADD > LEVLITE
> ADD > BERLEX LABS 0.02MG;0.1MG N20860 001
> ADD > JUL 13, 1998

TABLET; ORAL-21
LEVORA 0.15/30-21
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.03MG;0.15MG N73592 001
DEC 13, 1993

> ADD > TABLET; ORAL-28
> ADD > LEVLITE
> ADD > BERLEX LABS 0.02MG;0.1MG N20860 002
> ADD > JUL 13, 1998

LEVORA 0.15/30-28
AB [redacted] [redacted] [redacted]
AB WATSON LABS 0.03MG;0.15MG N73594 001
DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21
> DLT > AB [redacted] [redacted] [redacted]
> DLT >
> ADD > AB WATSON LABS 0.035MG;1MG N71480 001
> ADD > APR 12, 1988

TABLET; ORAL-28
NORETHIN 1/35E-28
> DLT > AB [redacted] [redacted] [redacted]
> DLT >
> ADD > AB WATSON LABS 0.035MG;1MG N71481 001
> ADD > APR 12, 1988

ETODOLAC

CAPSULE; ORAL
ETODOLAC
AB AESGEN 300MG N74929 001
JAN 30, 1998
AB TARO 200MG N75078 001
APR 30, 1998
AB 300MG N75078 002
APR 30, 1998

ETODOLAC

TABLET; ORAL
ETODOLAC

AB		CHELSEA LABS	400MG	N75069 001 APR 16, 1998
AB		MYLAN	400MG	N75104 001 FEB 06, 1998
AB		ROXCH LABS	400MG	N74892 001 APR 16, 1997
AB		TARO	400MG	N75074 001 MAR 11, 1998
AB		WATSON LABS	400MG	N74892 001 APR 16, 1997

TABLET, EXTENDED RELEASE; ORAL
LODINE XL

	+	WYETH AYERST	500MG	N20584 003 JAN 20, 1998

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP		MARSAM	20MG/ML	N74968 001 JAN 09, 1998

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

ETOPOPHOS PRESERVATIVE FREE

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996
	+		EQ 500MG BASE/VIAL	N20906 001 FEB 27, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

		MERCK	20MG	N20752 001 MAY 28, 1998

FAMOTIDINE

TABLET, ORALLY DISINTEGRATING; ORAL
PEPCID RPD

	+	MERCK	40MG	N20752 002 MAY 28, 1998

FENFLURAMINE HYDROCHLORIDE

TABLET; ORAL
PONDIMIN

	+	ROBINS AH	20MG	N16618 001
	●		20MG	N16618 001

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL

	●	ABBOTT	100MG	N19304 001 DEC 31, 1993
	●	LARS PHARMINK	100MG	N19304 001 DEC 31, 1993

TRICOR (MICRONIZED)

	+	ABBOTT	67MG	N19304 002 FEB 09, 1998

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE

AP		ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP		MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998
AP	+	JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FENTANYL CITRATE PRESERVATIVE FREE

AP		ABBOTT	EQ 0.05MG BASE/ML	N72786 001 SEP 24, 1991
AP	+	ELKINS SINN	EQ 0.05MG BASE/ML	N19101 001 JUL 11, 1984
AP		MARSAM	EQ 0.05MG BASE/ML	N74917 001 FEB 03, 1998

SUBLIMAZE PRESERVATIVE FREE

AP	+	JANSSEN	EQ 0.05MG BASE/ML	N16619 001

FLOSEQUINAN

TABLET; ORAL
FLOXOLAY
KNOLL PHARM — 50MG — [illegible]
75MG — [illegible]
* 100MG — [illegible]
@ 50MG — DEC 30, 1992
@ 75MG — N19960 002 DEC 30, 1992
@ 100MG — N19960 003 DEC 30, 1992

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
> ADD > AB DRAXIS HLTH — 0.05% — N72494 001 JAN 19, 1989
> ADD >
> DLT > AB TARO — 0.05% — [illegible]
> DLT >

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
AP PHARMACIA AND UPJOHN — 50MG/ML — [illegible]
AP * — 50MG/ML — N81225 001 AUG 28, 1991

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE
AO KING PHARMS — 25MG/ML — N74966 001 APR 16, 1998

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
CORDRAN-N
* LILLY — [illegible]
@ — 0.05%;EQ 3.5MG BASE/GM — N50346 001

OINTMENT; TOPICAL
CORDRAN-N
* LILLY — [illegible]
@ — 0.05%;EQ 3.5MG BASE/GM — N50345 001

FLUVOXAMINE MALEATE

TABLET; ORAL
LUVOX
@ SOLVAY — 25MG — [illegible]
25MG — N20243 001 DEC 05, 1994

GEMFIBROZIL

CAPSULE; ORAL
LOPID
@ PARKE DAVIS — 200MG — [illegible]
@ — 300MG — [illegible]
@ PARKE DAVIS PHARMS — 200MG — N18422 001
@ — 300MG — N18422 002

TABLET; ORAL
GEMFIBROZIL
AB TORPHARM — 600MG — N75034 001 JUL 20, 1998
LOPID
AB * PARKE DAVIS — 600MG — [illegible]
AB + PARKE DAVIS PHARMS — 600MG — N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN — EQ 40MG BASE/100ML — N62814 008 AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987
AP		EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005	AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007	
AP	MCGAW	[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	
AP		[redacted]	[redacted]	

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION
GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001	JUN 22, 1998

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	INVAMED	1.5MG	N75174 001	JUN 22, 1998
AB		3MG	N75174 002	JUN 22, 1998
AB	MYLAN	1.5MG	N74792 001	JUN 26, 1998
AB		3MG	N74792 002	JUN 26, 1998

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOSPORIN

AT	* GLAXO WELLCOME	[redacted]	[redacted]	
AT	+ MONARCH PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N60582 001	

GRANISETRON HYDROCHLORIDE

TABLET; ORAL
KYTRIL

●	SMITHKLINE BEECHAM	EQ 2MG BASE	N20305 002 JUN 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR

*	[redacted]	[redacted]	[redacted]
		EQ 200MG BASE	N20695 001 NOV 06, 1997
		EQ 400MG BASE	N20695 002 MAY 14, 1998
+		EQ 600MG BASE	N20695 003 MAY 14, 1998

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB	WATSON LABS	EQ 1MG BASE	N74762 001 JUN 25, 1997
AB		EQ 2MG BASE	N74762 002 JUN 25, 1997

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]
AB		[redacted]	[redacted]

> ADD >
> ADD >

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	[redacted]	[redacted]	[redacted]
AB		[redacted]	[redacted]
	●	0.5MG	N71071 001 NOV 03, 1986
	●	1MG	N71072 001 NOV 03, 1986
	●	2MG	N71073 001 NOV 03, 1986
	●	5MG	N71074 001 NOV 03, 1986
	●	10MG	N71075 001 AUG 04, 1987
	●	20MG	N71076 001 AUG 04, 1987

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AQ	BEDFORD	EQ 50MG BASE/ML	N74811 001 JAN 30, 1998

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	[redacted]	[redacted]	[redacted]
AP		[redacted]	[redacted]
	●	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
	●	EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

●	AM PHARM PARTNERS	10 UNITS/ML	N17029 017 DEC 05, 1985

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

> ADD >		@ AM PHARM PARTNERS	100 UNITS/ML	N17029 018 DEC 05, 1985	> DLT >
> ADD >					> DLT >
> DLT >		@ FUJISAWA	10 UNITS/ML	N17029 017 DEC 05, 1985	> DLT >
> DLT >					> DLT >
> DLT >		@	100 UNITS/ML	N17029 018 DEC 05, 1985	> DLT >
> DLT >					> DLT >

HEPARIN LOCK FLUSH

> ADD >	AP	AM PHARM PARTNERS	10 UNITS/ML	N17029 007 MAY 06, 1982	> DLT >
> ADD >					> DLT >
> ADD >	AP		100 UNITS/ML	N17029 006	> DLT >
> ADD >		@	100 UNITS/ML	N17651 010	> DLT >
> DLT >	AP	FUJISAWA	10 UNITS/ML	N17029 007 MAY 06, 1982	> DLT >
> DLT >					> DLT >
> DLT >	AP		100 UNITS/ML	N17029 006	> DLT >
> DLT >		@	100 UNITS/ML	N17651 010	> DLT >

HEPARIN LOCK FLUSH PRESERVATIVE FREE

> ADD >	@ AM PHARM PARTNERS	10 UNITS/ML	N17029 011 SEP 22, 1987	> DLT >
> ADD >				> DLT >
> ADD >	@	100 UNITS/ML	N17029 012 SEP 22, 1987	> DLT >
> ADD >				> DLT >
> DLT >	@ FUJISAWA	10 UNITS/ML	N17029 011 SEP 22, 1987	> DLT >
> DLT >				> DLT >
> DLT >	@	100 UNITS/ML	N17029 012 SEP 22, 1987	> DLT >
> DLT >				> DLT >

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

> ADD >	@ AM PHARM PARTNERS	10 UNITS/ML	N17029 008 SEP 22, 1987	> DLT >
> ADD >				> DLT >
> ADD >	@	100 UNITS/ML	N17029 009 SEP 22, 1987	> DLT >
> ADD >				> DLT >
> DLT >	@ FUJISAWA	10 UNITS/ML	N17029 008 SEP 22, 1987	> DLT >
> DLT >				> DLT >
> DLT >	@	100 UNITS/ML	N17029 009 SEP 22, 1987	> DLT >
> DLT >				> DLT >

HEPARIN SODIUM

> ADD >	AP	AM PHARM PARTNERS	[illegible]	N17029 001	> DLT >
> ADD >	AP			N17979 001	> DLT >
> ADD >	AP			N17651 006	> DLT >
> ADD >	AP			N17029 003	> DLT >
> ADD >	AP			N17979 002	> DLT >
> ADD >	AP			N17029 004	> DLT >
> ADD >	AP			N17651 005	> DLT >
> ADD >		@	5,000 UNITS/ML	N17029 002	> DLT >
> ADD >		@	5,000 UNITS/ML	N17979 003	> DLT >
> ADD >		@	10,000 UNITS/ML	N17651 003	> DLT >
> ADD >		@	20,000 UNITS/ML	N17651 008	> DLT >

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	FUJISAWA	[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
AP		[illegible]	[illegible]
	@	1,000 UNITS/ML	N17029 001
	@	2,000 UNITS/ML	N17979 001
	@	5,000 UNITS/ML	N17979 003
	@	10,000 UNITS/ML	N17651 003
	@	20,000 UNITS/ML	N17651 008

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
	@	200 UNITS/100ML	N19042 001 MAR 29, 1985
AP	MCGAW	200 UNITS/100ML	N19953 001 JUL 20, 1992
	@	200 UNITS/100ML	N19042 001 MAR 29, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985
	@	10,000 UNITS/100ML	N18911 006 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	N18911 007 JAN 30, 1985
	@	5,000 UNITS/100ML	N18911 007 JAN 30, 1985

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
		5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	B BRAUN	5,000 UNITS/100ML	N19802 001 JUL 20, 1992
@	MCGAW	5,000 UNITS/100ML	N19802 001 JUL 20, 1992

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ B BRAUN	200 UNITS/100ML	N19042 002 MAR 29, 1985		
	@ MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985		

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992		
AP	MCGAW	4,000 UNITS/100ML	N19952 001 JUL 20, 1992		

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

AP	ABBOTT	5,000 UNITS/100ML	N18911 009 JAN 30, 1985		
AP		10,000 UNITS/100ML	N18911 008 JAN 30, 1985		
	@	5,000 UNITS/100ML	N18911 009 JAN 30, 1985	> ADD >	
	@	10,000 UNITS/100ML	N18911 008 JAN 30, 1985	> ADD >	

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992	> ADD >	
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992	> DLT >	
	@	5,000 UNITS/100ML	N19134 001 MAR 29, 1985	> DLT >	
AP	MCGAW	5,000 UNITS/100ML	N19952 004 JUL 20, 1992	> DLT >	
AP		10,000 UNITS/100ML	N19952 005 JUL 20, 1992	> DLT >	
	@	5,000 UNITS/100ML	N19134 001 MAR 29, 1985	> ADD >	

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@ B BRAUN	5,000 UNITS/100ML	N19802 005 JUL 20, 1992	> DLT >	
	@	10,000 UNITS/100ML	N19802 002 JUL 20, 1992	> ADD >	
	@ MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992	> DLT >	
	@	10,000 UNITS/100ML	N19802 002 JUL 20, 1992	> DLT >	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ B BRAUN	5,000 UNITS/100ML	N19135 001 MAR 29, 1985		
	@	5,000 UNITS/100ML	N19802 003 JUL 20, 1992		
	@ MCGAW	5,000 UNITS/100ML	N19135 001 MAR 29, 1985		
	@	5,000 UNITS/100ML	N19802 003 JUL 20, 1992		

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ B BRAUN	1,000 UNITS/100ML	N19042 004 MAR 29, 1985		
	@ MCGAW	1,000 UNITS/100ML	N19042 004 MAR 29, 1985		

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985		
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985		
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985		
AP		20,000 UNITS/ML	N17029 016		
AP	FUJISAWA	1,000 UNITS/ML	[illegible]		
AP		5,000 UNITS/ML	[illegible]		
AP		10,000 UNITS/ML	[illegible]		
AP		20,000 UNITS/ML	[illegible]		

HEPARIN SODIUM PRESERVATIVE FREE

AP	+ AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986		
AP	+ FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986		

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009 JUN 26, 1984		
AP	FUJISAWA	10 UNITS/ML	N17651 009 JUN 26, 1984		

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVAPRO HCT

	● SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997	
	+	12.5MG;150MG	N20758 002 SEP 30, 1997	

IRBESARTAN-HYDROCHLOROTHIAZIDE

	● SANOFI	12.5MG;75MG	[illegible]	
	+	12.5MG;150MG	[illegible]	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	IVAX	[illegible]	[illegible]	
AB		[illegible]	[illegible]	
	●	15MG;250MG	N70829 001 MAR 09, 1987	
	●	25MG;250MG	N70830 001 MAR 09, 1987	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	25MG;25MG	N86881 001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

AB	GENEVA PHARMS	[illegible]	[illegible]	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N74970 001 JAN 06, 1998	>ADD> >ADD> >ADD> >ADD> >ADD>

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	BARR	25MG;37.5MG	N71251 002 MAY 05, 1998	>ADD> >ADD>

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

	NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998	
	+	12.5MG;160MG	N20818 002 MAR 06, 1998	

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

AT	PARKE DAVIS	2.5%	[illegible]
AT	PARKEDALE	2.5%	N88250 001 JUN 06, 1984

SOLUTION; TOPICAL

TEXACORT

AT	+ GERIMED	1%	[illegible]	
AT	+ MEDICIS	1%	N80425 001	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

CORTISPORIN

	● GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	[illegible]	
AT	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60613 001	

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

DILAUDID

AA	+ KNOLL PHARM	5MG/5ML	N19891 001 DEC 07, 1992	

HYDROMORPHONE HCL

AA	ROXANE	5MG/5ML	N74653 001 JUL 29, 1998	

TABLET; ORAL

DILAUDID

AB	+ KNOLL PHARM	8MG	N19892 001 DEC 07, 1992	

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HCL

> ADD >				
> ADD >	AB	ROXANE	8MG	N74597 001 JUL 29, 1998
> ADD				

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	1%;0.25%	N19261 001 JAN 30, 1992
+	ALLERGAN	1%;0.25%	N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	MYLAN	200MG	N40274 001 MAY 29, 1998

HYDROXYCHLOROQUINE SULFATE

AB	ROYCE LABS	200MG	N40133 001 NOV 30, 1995
AB	WATSON LABS	200MG	N40133 001 NOV 30, 1995

HYDROXYUREA

CAPSULE; ORAL

DROXIA

	BRISTOL MYERS SQUIBB	300MG	N16295 003 FEB 25, 1998
		200MG	N16295 002 FEB 25, 1998
		300MG	N16295 003 FEB 25, 1998
	+	400MG	N16295 004 FEB 25, 1998

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N16295 001
AB	+	SQUIBB	500MG	N16295 001

HYDROXYUREA

> ADD >	AB	DURAMED	500MG	N75020 001 JUL 30, 1998
> ADD >				

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

AB		ROYCE LABS	10MG	[illegible]
AB			25MG	[illegible]
AB			50MG	[illegible]
AB		WATSON LABS	10MG	N81149 001 MAR 18, 1994
AB			25MG	N81150 001 MAR 18, 1994
AB			50MG	N81151 001 MAR 18, 1994

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ADVIL

BX		AM HOME PRODS	100MG/5ML	[illegible]
BX		WHITEHALL ROBINS	100MG/5ML	N19833 002 SEP 19, 1989

IBUPROFEN

AB		ALPHARMA	100MG/5ML	N74978 001 MAR 25, 1998

MOTRIN

AB	+	MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989
RX	+		100MG/5ML	[illegible]

TABLET; ORAL

IBUPROFEN

AB		400MG	[illegible]
AB		600MG	[illegible]
AB		800MG	[illegible]
	@	400MG	[illegible]
	@	600MG	N72065 001 JAN 14, 1988
	@	800MG	N71938 001 JAN 14, 1988

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

> ADD >	AB	ALPHAPHARM	1.25MG	N75105 001	JUL 23, 1998
> ADD >					
> ADD >	AB		2.5MG	N75105 002	JUL 23, 1998
> ADD >					
	AB	TEVA	1.25MG	N74498 002	FEB 12, 1998

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	EON	75MG	N74464 001	MAY 28, 1998

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL

AP	ELKINS SINN	51%	N74629 004	MAR 31, 1998

IOPAMIDOL-250

AP	ABBOTT	51%	N75005 001	FEB 24, 1998

IOPAMIDOL-300

AP	ABBOTT	61%	N75005 002	FEB 24, 1998

IOPAMIDOL-370

AP	ABBOTT	76%	N75005 003	FEB 24, 1998

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 190

	[redacted]	40.6%	[redacted]	[redacted]
	BERLEX LABS	40.6%	N19580 001	DEC 07, 1989

OSMOVIST 240

	[redacted]	51.3%	[redacted]	[redacted]

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST 240

	BERLEX LABS	51.3%	N19580 002	DEC 07, 1989

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 240

+	MALLINCKRODT	51%	N20923 001	MAY 28, 1998

OPTIRAY 320

+	MALLINCKRODT	68%	N20923 002	MAY 29, 1998

OPTIRAY 350

+	MALLINCKRODT	74%	N20923 003	MAY 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION
ATROVENT

	[redacted]	0.018MG/INH	[redacted]	[redacted]
+		0.018MG/INH	N19085 001	DEC 29, 1986

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
[redacted]

> DLT >				
> DLT >	[redacted]	[redacted]	[redacted]	[redacted]
> DLT >				
> DLT >		[redacted]	[redacted]	[redacted]
> DLT >				
> ADD >	@	2.5MG	N16191 002	APR 01, 1996
> ADD >				
> ADD >	@	5MG	N16191 001	APR 01, 1996
> ADD >				

ISOSULFAN BLUE

INJECTABLE; INJECTION
LYMPHAZURIN

*	[illegible]	1%		N18310 001	>DLT>
+	US SURGCL	1%		N18310 001	>DLT>

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP	*	PARKE DAVIS	[illegible]	N16812 002	>ADD>
AP	*			N16812 003	>ADD>
	*			N16812 001	>DLT>
AP	+	PARKEDALE		N16812 002	>DLT>
AP	+			N16812 003	
	+			N16812 001	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

*	WYETH AYERST	100MG		N19816 003
				FEB 08, 1995
*		150MG		N19816 002
				FEB 08, 1995
		100MG		N19816 003
				FEB 08, 1995
		150MG		N19816 002
				FEB 08, 1995

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN

+	HOECHST MARION RSSL	50MG/VIAL		N20807 001
				MAR 06, 1998

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN

>ADD>	+	ICN	2MG/ML	N08719 001	
>ADD>				DEC 19, 1991	

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION
LEVO-DROMORAN

*	[illegible]	2MG/ML		[illegible]
				DEC 19, 1991

TABLET; ORAL
LEVO-DROMORAN

>ADD>	+	ICN	2MG	N08720 001
>ADD>				DEC 19, 1991
>DLT>	*	[illegible]	2MG	[illegible]
>DLT>				DEC 19, 1991

LIDOCAINE

DISC; ORAL
XYLOCAINE

	[illegible]	10%		N14394 001
+	ASTRA PHARMS	10%		N14394 001

LIDOCAINE; PRILOCAINE

DISC; TOPICAL
EMLA

+	ASTRA PHARMS	2.5%;2.5%		N20962 001
				FEB 04, 1998

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

AP	AM PHARM PARTNERS	2%		N17584 001
AP		4%		N17584 002
AP	FUJISAWA	4%		N17584 001
AP		4%		N17584 002

LISINOPRIL

TABLET; ORAL
ZESTRIL

AB	* ZENECA	2.5MG		N19777 005
				APR 29, 1993
AB		2.5MG		N19777 005
				APR 29, 1993

LISINOPRIL

TABLET; ORAL

	ZESTRIL			N19777 002
AB	ZENECA	10MG		MAY 19, 1988
AB	+	10MG		N19777 002 MAY 19, 1988

LORATADINE

TABLET; ORAL

	CLARITIN REDITABS		N20704 001
	SCHERING	10MG	DEC 23, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

	CLARITIN REDITABS		N20704 001
+	SCHERING	10MG	DEC 23, 1996

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
> ADD >	AP	AKORN	2MG/ML	N74974 001 JUL 23, 1998
> ADD >				N75025 001
> ADD >	AP	TAYLOR	2MG/ML	JUL 23, 1998
> ADD >				

TABLET; ORAL

	LORAZEPAM			
AB	ROYCE LABS	0.5MG		N72926 001 OCT 31, 1991
AB		1MG		N72927 001 OCT 31, 1991
AB		2MG		N72928 001 OCT 31, 1991
AB	WATSON LABS	0.5MG		N72926 001 OCT 31, 1991
AB		1MG		N72927 001 OCT 31, 1991
AB		2MG		N72928 001 OCT 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

	ALREX			N20803 001
+	PHARMOS	0.2%		MAR 09, 1998
	LOTEMAX			N20583 001
+	PHARMOS	0.5%		MAR 09, 1998
+		0.5%		N20841 001 MAR 09, 1998

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

	LOXITANE C		
*	COCRYSTS	EQ 25MG BASE/ML	N17658 001
+	WATSON LABS	EQ 25MG BASE/ML	N17658 001

INJECTABLE; INJECTION

	LOXITANE IM		
*	COCRYSTS	EQ 50MG BASE/ML	N18039 001
+	WATSON LABS	EQ 50MG BASE/ML	N18039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXITANE			
AB	COCRYSTS			N17525 001
AB				N17525 002
AB	*			N17525 003
AB				N17525 004
AB	WATSON LABS			N17525 001
AB				N17525 002
AB				N17525 003
AB	+			N17525 004

TABLET; ORAL

	LOXITANE			
@	COCRYSTS			N17525 006
@				N17525 007
@				N17525 008
@	WATSON LABS	EQ 10MG BASE		N17525 006
@		EQ 25MG BASE		N17525 007
@		EQ 50MG BASE		N17525 008

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
+ BERTEK PHARMS — EQ 85MG BASE/GM — N16763 001
# [illegible] — [illegible] — [illegible]

POWDER FOR RECONSTITUTION; TOPICAL
SULFAMYLON
+ MYLAN — 5% — N19832 003 JUN 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN — 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML — N19696 001 SEP 29, 1989
MCGAW — [illegible] — [illegible]

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN — 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML — N18252 001
AP — 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML — N19711 001 SEP 29, 1989
AP MCGAW — [illegible] — [illegible]
AP — [illegible] — [illegible]

MALATHION

LOTION; TOPICAL
OVIDE
[illegible] — [illegible] — [illegible]
@ MEDICIS — 0.5% — N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP B BRAUN — 10GM/100ML — N20006 002 JUL 26, 1993
AP MCGAW — [illegible] — [illegible]

MANNITOL 15% IN PLASTIC CONTAINER
AP B BRAUN — 15GM/100ML — N20006 003 JUL 26, 1993
AP MCGAW — [illegible] — [illegible]

MANNITOL 20%
AP B BRAUN — 20GM/100ML — N14738 001
AP MCGAW — [illegible] — [illegible]

MANNITOL 20% IN PLASTIC CONTAINER
AP B BRAUN — 20GM/100ML — N20006 004 JUL 26, 1993
AP MCGAW — [illegible] — [illegible]

MANNITOL 5% IN PLASTIC CONTAINER
AP B BRAUN — 5GM/100ML — N20006 001 JUL 26, 1993
AP MCGAW — [illegible] — [illegible]

SOLUTION; IRRIGATION
RESECTISOL IN PLASTIC CONTAINER
B BRAUN — 5GM/100ML — N16772 002
MCGAW — [illegible] — [illegible]

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL
INVERSINE
+ LAYTON — 2.5MG — N10251 001
# MERCK SHARP DOHME — [illegible] — [illegible]

MEGESTROL ACETATE

TABLET; ORAL

		MEGESTROL ACETATE		
AB		PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

		MEPERIDINE HCL		
AA		ROYCE LABS	50MG	[illegible]
AA		WATSON LABS	50MG	N40186 001 JUN 30, 1997

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

			PENTASA		
> DLT >		*	HOECHST MARION RESL	250MG	[illegible]
> DLT >					
> ADD >		+	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993
> ADD >					

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

			NORETHIN 1/50M-21		
> DLT >	AB		SEARLE	0.05MG;1MG	[illegible]
> DLT >					
> ADD >	AB		WATSON LABS	0.05MG;1MG	N71539 001 APR 12, 1988
> ADD >					

TABLET; ORAL-28

			NORETHIN 1/50M-28		
> DLT >	AB		SEARLE	0.05MG;1MG	[illegible]
> DLT >					
> ADD >	AB		WATSON LABS	0.05MG;1MG	N71540 001 APR 12, 1988
> ADD >					

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

		METHADONE HCL		
AA		ROXANE	10MG/ML	N40180 001 APR 30, 1998

TABLET; ORAL

		METHADONE HCL		
AA		EON	5MG	N40241 001 MAY 29, 1998
AA			10MG	N40241 002 MAY 29, 1998

TABLET, DISPERSIBLE; ORAL

		METHADONE HCL		
AA		EON	40MG	N75082 001 MAR 25, 1998

METHOCARBAMOL

INJECTABLE; INJECTION

		METHOCARBAMOL		
AP		ROXANE	[illegible]	[illegible]
	●		100MG/ML	N89849 001 DEC 27, 1991

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

		METOCLOPRAMIDE HCL		
AB		[illegible]	[illegible]	[illegible]
AB			[illegible]	[illegible]
	●		EQ 5MG BASE	N72436 001 JUN 22, 1989
	●		EQ 10MG BASE	N70850 001 FEB 03, 1987

METOPROLOL TARTRATE

INJECTABLE; INJECTION

			METOPROLOL TARTRATE		
> ADD >	AP		ABBOTT	1MG/ML	N75160 001 JUL 06, 1998
> ADD >					

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	DANBURY PHARMA	150MG	N74865 001	APR 13, 1998
AB		200MG	N74865 002	APR 13, 1998
AB		250MG	N74865 003	APR 13, 1998

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	SUPERGEN	5MG/VIAL	N64144 001	APR 30, 1998
AP		20MG/VIAL	N64144 002	APR 30, 1998

MONTELUKAST SODIUM

TABLET; ORAL
SINGULAIR

+	MERCK	EQ 10MG BASE	N20829 002	FEB 20, 1998

TABLET, CHEWABLE; ORAL
SINGULAIR

+	MERCK	EQ 5MG BASE	N20830 001	FEB 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

> ADD >	+ FAULDING	20MG	N20616 001	JUL 03, 1996
> ADD >	+	50MG	N20616 002	JUL 03, 1996
> ADD >	+	100MG	N20616 003	JUL 03, 1996
> DLT >	* FAULDING SVCS	20MG	N20616 001	JUL 03, 1996
> DLT >	*	50MG	N20616 002	JUL 03, 1996

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

> DLT >	* FAULDING SVCS	20MG	[illegible]	[illegible]
> DLT >				

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

> ADD >	AB	AB GENERICS	15MG	N74862 001 JUL 07, 1998
> ADD >	AB		30MG	N74862 002 JUL 07, 1998
> ADD >	AB		60MG	N74862 003 JUL 07, 1998
> ADD >	AB		100MG	N74769 001 JUL 02, 1998
> ADD >	AB		200MG	N74769 002 JUL 02, 1998

MS CONTIN

> ADD >	AB	+	PURDUE FREDERICK	15MG	N19516 003 SEP 12, 1989
> ADD >	AB	+		30MG	N19516 001 MAY 29, 1987
> ADD >	AB	+		60MG	N19516 002 APR 08, 1988
> ADD >	AB	+		100MG	N19516 004 JAN 16, 1990
> ADD >	AB	+		200MG	N19516 005 [illegible]
> DLT >	BC	*		15MG	[illegible]
> DLT >	BC	*		30MG	[illegible]
> DLT >	BC	*		60MG	[illegible]
> DLT >	BC	*		100MG	[illegible]

NADOLOL

TABLET; ORAL
CORGARD

> ADD >	AB	BRISTOL MYERS SQUIBB	20MG	N18063 005 OCT 28, 1986
> ADD >	AB		40MG	N18063 001
> ADD >	AB		80MG	N18063 002
> ADD >	AB		120MG	N18063 003

NADOLOL

TABLET; ORAL
CORGARD

> ADD >	AB	+	BRISTOL MYERS SQUIBB	160MG	[illegible]
> DLT >	AB		SQUIBB	[illegible]	
> DLT >					
> DLT >	AB			[illegible]	
> DLT >	AB			[illegible]	
> DLT >	AB			[illegible]	
> DLT >	AB	*		[illegible]	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP		KING PHARMS	10MG/ML	N74471 001 MAR 19, 1998
AP			20MG/ML	N74471 002 MAR 19, 1998

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP		ABBOTT	[illegible]	[illegible]
	@		0.4MG/ML	N70172 001 SEP 24, 1986

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB		ROXCH LABS	[illegible]	[illegible]
AB		WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001 JAN 21, 1997

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL

AB		BARR	50MG	N74918 001 MAY 08, 1998

REVIA

AB	+	DUPONT MERCK	50MG	N18932 001 NOV 20, 1984

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
EC-NAPROSYN

AB	+	SYNTEX	375MG	N20067 002 OCT 14, 1994
AB	+		500MG	N20067 003 OCT 14, 1994

NAPROXEN

AB		INVAMED	375MG	N75061 001 FEB 18, 1998
AB			500MG	N75061 002 FEB 18, 1998
AB		PUREPAC PHARM	375MG	N74936 001 FEB 24, 1998
AB			500MG	N74936 002 FEB 24, 1998
AB		TEVA	375MG	N75227 001 JUN 30, 1998
AB			500MG	N75227 002 JUN 30, 1998

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB		AL HIKMA	EQ 250MG BASE	N74480 002 FEB 18, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
AMERGE

		GLAXO WELLCOME	EQ 1MG BASE	N20763 002 FEB 10, 1998

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

	AMERGE			
+	GLAXO WELLCOME	EQ 2.5MG BASE	N20763 001	FEB 10, 1998

NEOMYCIN SULFATE

TABLET; ORAL

	NEOMYCIN SULFATE			
	TEVA	EQ 350MG BASE	N60304 001	
+		EQ 350MG BASE	N60304 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

	NEOSPORIN G.U. IRRIGANT			
AT	GLAXO WELLCOME	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	
AT	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001	

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

	NICARDIPINE HCL			
AB	GENPHARM	20MG	N74928 001	MAR 19, 1998
AB		30MG	N74928 002	MAR 19, 1998

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN			
AB	3N	0.1MG/HR	N89771 001	AUG 30, 1996
AB1		0.1MG/HR	N89771 001	AUG 30, 1996
AB		0.2MG/HR	N89772 001	AUG 30, 1996
AB1		0.2MG/HR	N89772 001	AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	MINITRAN			
AB	3N	0.4MG/HR	N89773 001	AUG 30, 1996
AB1		0.4MG/HR	N89773 001	AUG 30, 1996
AB		0.6MG/HR	N89774 001	AUG 30, 1996
AB1		0.6MG/HR	N89774 001	AUG 30, 1996
	NITRO-DUR			
AB	* KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
AB1	+	0.1MG/HR	N20145 001	APR 04, 1995
AB	*	0.2MG/HR	N20145 002	APR 04, 1995
AB1	+	0.2MG/HR	N20145 002	APR 04, 1995
AB	*	0.4MG/HR	N20145 004	APR 04, 1995
AB1	+	0.4MG/HR	N20145 004	APR 04, 1995
AB	*	0.6MG/HR	N20145 005	APR 04, 1995
AB1	+	0.6MG/HR	N20145 005	APR 04, 1995
	NITROGLYCERIN			
AB2	MYLAN	0.1MG/HR	N75033 001	FEB 06, 1998
AB		0.2MG/HR	N74609 001	AUG 30, 1996
AB2		0.2MG/HR	N74609 001	AUG 30, 1996
AB		0.4MG/HR	N74607 001	AUG 30, 1996
AB2		0.4MG/HR	N74607 001	AUG 30, 1996
AB		0.6MG/HR	N74559 001	AUG 30, 1996
AB2		0.6MG/HR	N74559 001	AUG 30, 1996
	TRANSDERM-NITRO			
AB2	+ NOVARTIS	0.1MG/HR	N20144 001	FEB 27, 1996
AB	*	0.2MG/HR	N20144 002	FEB 27, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM-NITRO

AB2	+	NOVARTIS	0.2MG/HR	N20144 002 FEB 27, 1996
AB	*		0.4MG/HR	N20144 003 FEB 27, 1996
AB2	+		0.4MG/HR	N20144 003 FEB 27, 1996
AB	*		0.6MG/HR	N20144 004 FEB 27, 1996
AB2	+		0.6MG/HR	N20144 004 FEB 27, 1996
BX	*		0.1MG/HR	N20144 001 FEB 27, 1996

NORETHINDRONE

TABLET; ORAL

NOR-QD

*	CHARLES	0.35MG	N17060 001
+	WATSON LABS	0.35MG	N17060 001

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	UDL	100,000 UNITS/ML	N64142 001 JUN 25, 1998

OLANZAPINE

TABLET; ORAL

ZYPREXA

> ADD >		@ LILLY	15MG	N20592 005 SEP 09, 1997
> ADD >				
> ADD >		@	20MG	N20592 006 SEP 09, 1997
> ADD >				

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PRILOSEC

	+	ASTRA MERCK	40MG	N19810 002 JAN 15, 1998

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

AB	+	3M	100MG	N12157 001

ORPHENADRINE CITRATE

AB		INVAMED	100MG	N40284 001 JUN 19, 1998

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

AA	+	ALZA	5MG/5ML	N18211 001
AA	*	[illegible]	[illegible]	[illegible]

TABLET; ORAL

DITROPAN

AB	+	ALZA	5MG	N17577 001
AB	*	[illegible]	[illegible]	[illegible]

OXYTOCIN

INJECTABLE; INJECTION

PITOCIN

AP	*	[illegible]	[illegible]	[illegible]
AP	+	PARKEDALE	10 USP UNITS/ML	N18261 001

PARICALCITOL

INJECTABLE; INJECTION

ZEMPLAR

	+	ABBOTT	0.005MG/ML	N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AB	+	PARKE DAVIS	EQ 250MG BASE	N60311 001
AB			EQ 250MG BASE	N62310 001
AB	+	PARKEDALE	EQ 250MG BASE	N60521 001
AB			EQ 250MG BASE	N62310 001

PAROMOMYCIN SULFATE

AA		CARACO	EQ 250MG BASE	N64171 001 JUN 30, 1997

PAROMOMYCIN SULFATE

CAPSULE; ORAL
PAROMOMYCIN SULFATE

AB	CARACO	EQ 250MG BASE	N64171 001 JUN 30, 1997	

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL
ELMIRON

+	ALZA	100MG	N20193 001 SEP 26, 1996	
*	BAKER NORTON	100MG	N20193 001 SEP 26, 1996	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

> ADD >	AB	BIOVAIL	400MG	N75028 001 JUL 20, 1998	
> ADD >					

PERMETHRIN

CREAM; TOPICAL
ELIMITE

AB	+ ALLERGAN	5%	N19855 001 AUG 25, 1989	

PERMETHRIN

AB	ALPHARMA	5%	N74806 001 JAN 23, 1998	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL
AZO GANTRISIN

*	ROCHE	50MG;500MG	N19358 001 AUG 31, 1990	
@		50MG;500MG	N19358 001 AUG 31, 1990	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	ECR	37.5MG	N88414 001 OCT 19, 1983	
@		37.5MG	N88414 001 OCT 19, 1983	

TABLET; ORAL
PHENTERMINE HCL

*	ECR	30MG	N88605 001 SEP 28, 1987	
@		30MG	N88605 001 SEP 28, 1987	

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION
PHENTOLAMINE MESYLATE

AP	BEDFORD	5MG/VIAL	N40235 001 MAR 11, 1998	

REGITINE

AP	+ NOVARTIS	5MG/VIAL	N08278 003	

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	PUREPAC PHARM	5MG	N74125 001 APR 28, 1993	
AB		10MG	N74125 002 APR 28, 1993	
@		5MG	N74125 001 APR 28, 1993	
@		10MG	N74125 002 APR 28, 1993	
AB	ROYCE LABS	5MG	N74437 001 FEB 27, 1995	
AB		10MG	N74437 002 FEB 27, 1995	
AB	WATSON LABS	5MG	N74437 001 FEB 27, 1995	
AB		10MG	N74437 002 FEB 27, 1995	

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN IN PLASTIC CONTAINER

+	LEDERLE	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001	FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	ROYCE LABS	10MG	N74460 001	SEP 29, 1995
AB		20MG	N74460 002	SEP 29, 1995
AB	WATSON LABS	10MG	N74460 001	SEP 29, 1995
AB		20MG	N74460 002	SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
PEG-LYTE

AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001	AUG 31, 1993
	@	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001	AUG 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

AP	+ GLAXO WELLCOME	EQ 500,000 U BASE/VIAL	N62036 001	
	@	EQ 500,000 U BASE/VIAL	N62036 001	

POLYMYXIN B SULFATE

> ADD > AP	+ BEDFORD	EQ 500,000 U BASE/VIAL	N60716 001	

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
POLYMYXIN B SULFATE

> DLT > AP	PFIZER	EQ 500,000 U BASE/VIAL	N60716 001	

POWDER; FOR RX COMPOUNDING
POLY-RX

AA	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001	
	+	100,000,000 UNITS/BOT	N61578 001	

POLYMYXIN B SULFATE

AA	PADDOCK	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983
	@	100,000,000 UNITS/BOT	N62455 001	JUL 27, 1983

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	APR 13, 1998

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	B BRAUN	2MEQ/ML	N85870 001	
AP	MCGAW	2MEQ/ML	N85870 001	

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

@	B BRAUN	75MG/100ML;900MG/100ML	N18722 001	NOV 09, 1982
@	MCGAW	75MG/100ML;900MG/100ML	N18722 001	NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

@	B BRAUN	150MG/100ML;900MG/100ML	N18722 002	NOV 09, 1982
@	MCGAW	150MG/100ML;900MG/100ML	N18722 002	NOV 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

@	B BRAUN	220MG/100ML;900MG/100ML	N18722 003 NOV 09, 1982
@	MCGAW	220MG/100ML;900MG/100ML	N18722 003 NOV 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@	B BRAUN	300MG/100ML;900MG/100ML	N18722 004 NOV 09, 1982
@	MCGAW	300MG/100ML;900MG/100ML	N18722 004 NOV 09, 1982

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

	PHARMACIA AND UPJOHN	0.5MG	N20667 006 FEB 12, 1998

PREDNISOLONE

SYRUP; ORAL

PRE-PRED

>DLT>	AA		WE PHARMS	15MG/5ML	N40192 001 MAY 28, 1998
>DLT>					

PREDNISOLONE

>ADD>	AA		WE PHARMS	15MG/5ML	N40192 001 MAY 28, 1998
>ADD>					

PRELONE

	AA	+	MURO	15MG/5ML	N89081 001 FEB 04, 1986

TABLET; ORAL

PREDNISOLONE

	BX		DANBURY PHARMA	5MG	N80354 001
	BX	+		5MG	N80354 001
	BX	+	GENEVA PHARMS	5MG	N80339 001
		@		5MG	N80339 001

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

		+	ELAN PHARMA	250MG/5ML	N10401 001
		+	WYETH AYERST	250MG/5ML	N10401 001

TABLET; ORAL

MYSOLINE

	AB	+	ELAN PHARMA	250MG	N09170 002
		+		50MG	N09170 003
	AB	+	WYETH AYERST	250MG	N09170 002
		+		50MG	N09170 003

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

AB		INVAMED	500MG	N89284 001 JUN 23, 1986
	@		500MG	N89284 001 JUN 23, 1986
AB		SIDMAK LABS NJ	250MG	N88958 001 DEC 02, 1985
	@		250MG	N88958 001 DEC 02, 1985

PROCAN SR

AB		PARKE DAVIS	500MG	N86065 001
AB			750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985
AB	+	PARKEDALE	500MG	N86065 001
AB	+		750MG	N87510 001 APR 01, 1982
AB	+		1GM	N88489 001 JAN 16, 1985

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP		MARSAM	EQ 5MG BASE/ML	N89675 001 DEC 05, 1988
	@		EQ 5MG BASE/ML	N89675 001 DEC 05, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	TRIGEN	EQ 5MG BASE	N40268 001	FEB 27, 1998
AB		EQ 10MG BASE	N40268 002	FEB 27, 1998
AB	ZENITH GOLDLINE	EQ 5MG BASE	N40162 001	JAN 20, 1998
AB		EQ 10MG BASE	N40162 002	JAN 20, 1998

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

+	SCHERING PLOUGH	100MG	N19781 001	MAY 14, 1998

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	MARSAN	25MG/ML	N89463 001	MAY 02, 1988
AP		50MG/ML	N89477 001	MAY 02, 1988
@		25MG/ML	N89463 001	MAY 02, 1988
@		50MG/ML	N89477 001	MAY 02, 1988

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

AA	PUREPAC PHARM	65MG	N83278 001	
@		65MG	N83278 001	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	INVANED	10MG	N71658 001	JUL 05, 1988

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	INVANED	20MG	[illegible]	
AB		40MG	[illegible]	
AB		60MG	[illegible]	
AB		80MG	[illegible]	
AB		90MG	[illegible]	
@		10MG	N71658 001	JUL 05, 1988
@		20MG	N71687 001	JUL 05, 1988
@		40MG	N71688 001	JUL 05, 1988
@		60MG	N72197 001	JUL 05, 1988
@		80MG	N71689 001	JUL 05, 1988
@		90MG	N72198 001	JUL 05, 1988

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	PUREPAC PHARM	200MG	N84003 001	
@		200MG	N84003 001	

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB	+ ROBINS AH	300MG	N12796 002	
AB	+ WYETH AYERST	300MG	N12796 002	

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL
ZANTAC

	GLAXO WELLCOME	EQ 15MG BASE/ML	N19675 001	DEC 30, 1988
+		EQ 15MG BASE/ML	N19675 001	DEC 30, 1988


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
6"

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

>ADD>	AB	MYLAN	EQ 150MG BASE	N74552 001	
>ADD>				JUL 30, 1998	
>ADD>	AB		EQ 300MG BASE	N74552 002	
>ADD>				JUL 30, 1998	
	AB	RANBAXY	EQ 150MG BASE	N75000 001	
				JAN 30, 1998	
	AB		EQ 300MG BASE	N75000 002	
				JAN 30, 1998	

RIFAMPIN

CAPSULE; ORAL
RIFADIN

AB	HOECHST MARION RSSL	150MG	N62303 001	

RIFAMPIN

AB	EON	150MG	N64150 002	
			JAN 02, 1998	

RIFAPENTINE

TABLET; ORAL
PRIFTIN

+	HOECHST MARION RSSL	150MG	N21024 001	
			JUN 22, 1998	

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

+	PROCTER AND GAMBLE	30MG	N20835 001	
			MAR 27, 1998	

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT

>DLT>	MERCK	EQ 5MG BASE	N20864 001	
>DLT>			JUN 29, 1998	
>DLT>	+	EQ 10MG BASE	N20864 002	
>DLT>			JUN 29, 1998	

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT

>ADD>	MERCK	EQ 5MG BASE	N20864 001	
>ADD>			JUN 29, 1998	
>ADD>	+	EQ 10MG BASE	N20864 002	
>ADD>			JUN 29, 1998	

MAXALT-MLT

	MERCK	EQ 5MG BASE	N20865 001	
			JUN 29, 1998	
	+	EQ 10MG BASE	N20865 002	
			JUN 29, 1998	

SACROSIDASE

SOLUTION; ORAL
SUCRAID

+	ORPHAN MEDCL	8,500 IU/ML	N20772 001	
			APR 09, 1998	

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE

*	ROCHE	EQ 200MG BASE	N20828 001	
			NOV 07, 1997	
+		200MG	N20828 001	
			NOV 07, 1997	

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HCL

AB	ESI LEDERLE	5MG	N74641 001	
			AUG 02, 1996	
AB	LEDERLE	5MG	N74641 001	
			AUG 02, 1996	
AB	STASON	5MG	N74912 001	
			APR 30, 1998	

SILDENAFIL CITRATE

TABLET; ORAL

	VIAGRA			
	PFIZER	25MG	N20895 001	MAR 27, 1998
		50MG	N20895 002	MAR 27, 1998
+		100MG	N20895 003	MAR 27, 1998

SIMVASTATIN

TABLET; ORAL

	ZOCOR			
> DLT >	MERCK	5MG	N19766 001	DEC 23, 1991
> DLT >		40MG	N19766 004	DEC 23, 1991
> DLT >				
> DLT >	+	5MG	N19766 001	DEC 23, 1991
> ADD >				
> ADD >		40MG	N19766 004	DEC 23, 1991
> ADD >				
> ADD >	+	80MG	N19766 005	JUL 10, 1998
> ADD >				

SODIUM CHLORIDE

INJECTABLE; INJECTION

	SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	450MG/100ML	N19635 001	MAR 09, 1988
@		450MG/100ML	N18184 001	
AP	MCGAW	450MG/100ML	N19635 001	MAR 09, 1988
@		450MG/100ML	N18184 001	
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	B BRAUN	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002	MAR 09, 1988
AP	MCGAW	900MG/100ML	N17464 001	
AP		900MG/100ML	N19635 002	MAR 09, 1988
	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER			
@	B BRAUN	3GM/100ML	N19635 003	MAR 09, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION

	SODIUM CHLORIDE 3% IN PLASTIC CONTAINER			
@	MCGAW	3GM/100ML	N19635 003	MAR 09, 1988
	SODIUM CHLORIDE 5% IN PLASTIC CONTAINER			
@	B BRAUN	5GM/100ML	N19635 004	MAR 09, 1988
@	MCGAW	5GM/100ML	N19635 004	MAR 09, 1988

SODIUM LACTATE

INJECTABLE; INJECTION

	SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER			
@	B BRAUN	1.87GM/100ML	N18186 001	
@	MCGAW	1.87GM/100ML	N18186 001	
	SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER			
AP	B BRAUN	1.87GM/100ML	N20004 001	APR 21, 1992
AP	MCGAW	1.87GM/100ML	N20004 001	APR 21, 1992

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

	KAYEXALATE			
AA	SANOFI	453.6GM/BOT	N11287 001	
AA	+	453.6GM/BOT	N11287 001	
	KIONEX			
AA	PADDOCK	454GM/BOT	N40029 001	FEB 06, 1998

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE			
@	BERLEX LABS	120MG	N19865 003	APR 20, 1994
		160MG	N19865 002	OCT 30, 1992
+		240MG	N19865 001	OCT 30, 1992
		120MG	N19865 005	APR 20, 1994

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

+	BERLEX LABS	160MG	N19865 002	OCT 30, 1992
		240MG	N19865 003	OCT 30, 1992

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 30%

AP	+ PHARMACIA AND UPJOHN	30%	N19942 001	DEC 30, 1993

LIPOSYN III 30%

AP	+ ABBOTT	30%	N20181 001	JAN 13, 1998

NUTRILIPID 10%

AP	+ B BRAUN	10%	N19531 001	MAY 28, 1993
AP	* MCGAW	10%	N19531 001	MAY 28, 1993

NUTRILIPID 20%

AP	+ B BRAUN	20%	N19531 002	MAY 28, 1993
AP	* MCGAW	20%	N19531 002	MAY 28, 1993

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

AP	+ PFIZER	EQ 1GM BASE/VIAL	N60076 001	
		EQ 1GM BASE/2.5ML	N60111 001	
	+	EQ 1GM BASE/2.5ML	N60111 001	
AP	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCOSTRIN

AP	* ANTHECON	20MG/ML	N08847 001	
	●	20MG/ML	N08847 001	

> DLT >
> DLT >
> DLT >

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	RATIOPHARM	1GM	N74415 001	JUN 08, 1998

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA

AP	+ AKORN	EQ 0.05MG BASE/ML	N19050 001	MAY 04, 1984
AP	* JANSSEN	EQ 0.05MG BASE/ML	N19050 001	MAY 04, 1984

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

AT	CIBA	10%	N80025 001	
	●	10%	N80025 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

GENERIC FORMULATIC

AB	TEVA	200MG/5ML;40MG/5ML	N70028 002	JUN 02, 1987

SMZ-TMP

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983

SMZ-TMP PEDIATRIC

AB	TEVA	200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	TEVA	200MG/5ML;40MG/5ML	N18812 001	JAN 28, 1983
AB		200MG/5ML;40MG/5ML	N18812 002	JUN 10, 1983
AB		200MG/5ML;40MG/5ML	N70028 001	JUN 02, 1987

> ADD >
> ADD >

TABLET; ORAL

SMZ-TMP

AB	TEVA	400MG;80MG	N18742 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	[redacted]		
AB	TEVA	[redacted]	[redacted]
	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AB	TEVA	400MG;80MG	N18242 001
AB		800MG;160MG	N18242 002

SULFASALAZINE

TABLET; ORAL

	SULFASALAZINE		
AB	SUPERPHARM	500MG	[redacted] OCT 26, 1987
	◉	500MG	N89339 001 OCT 26, 1987

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

	COGNEX		
	PARKE DAVIS	EQ 10MG BASE	[redacted]
		EQ 20MG BASE	[redacted]
		EQ 30MG BASE	[redacted]
	‡	EQ 40MG BASE	[redacted]
	PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993
	+	EQ 40MG BASE	N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL

	PROGRAF		
	‡ FUJISAWA	[redacted]	[redacted]

TACROLIMUS

CAPSULE; ORAL

	PROGRAF		
	‡ FUJISAWA	EQ 5MG BASE	[redacted] APR 08, 1994
	+ FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001 APR 08, 1994
	+	EQ 5MG BASE	N50708 002 APR 08, 1994

INJECTABLE; INJECTION

	PROGRAF		
	‡ FUJISAWA	EQ 5MG BASE/ML	[redacted] APR 08, 1994
	+ FUJISAWA HLTHCARE	EQ 5MG BASE/ML	N50709 001 APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

	TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT		
BS	DRAXIMAGE	N/A	N17881 001 DEC 30, 1987
BS	MERCK SHARP DOHME	N/A	[redacted] DEC 30, 1987

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

	HEPATOLITE		
	DUPONT	N/A	[redacted] MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

	TECHNESCAN GLUCEPTATE		
AP	DRAXIMAGE	N/A	N18272 001 JAN 27, 1982
AP	MERCK SHARP DOHME	N/A	[redacted] JAN 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE	N/A	N18489 001 OCT 31, 1986
	MERCK	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
TECHNESCAN MDP KIT

AP	DRAXIMAGE	N/A	N18035 001
AP	MERCK SHARP DOHME	N/A	N18035 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

AP	DRAXIMAGE	N/A	N18511 001 DEC 29, 1989
AP	MERCK	N/A	N18511 001 DEC 29, 1989

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
AM-SULFUR COLLOID

AP	CIS	N/A	N17858 001
	@	N/A	N17858 001

TECHNOLOID

> DLT >	AP	BRACCO	N/A	N16923 001
> DLT >		@	N/A	N16923 001
> ADD >				

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 1MG BASE	N20347 001 DEC 14, 1994	
AB	+	EQ 2MG BASE	N20347 002 DEC 14, 1994	> DLT >
AB		EQ 5MG BASE	N20347 003 DEC 14, 1994	> DLT >

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
HYTRIN

AB	ABBOTT	EQ 10MG BASE	N20347 004 DEC 14, 1994	

TERAZOSIN HCL

AB	GENEVA PHARMS	EQ 1MG BASE	N74823 001 MAR 30, 1998	
AB		EQ 2MG BASE	N74823 002 MAR 30, 1998	
AB		EQ 5MG BASE	N74823 003 MAR 30, 1998	
AB		EQ 10MG BASE	N74823 004 MAR 30, 1998	

TERBINAFINE

GEL; TOPICAL
LAMISIL

	+ NOVARTIS	1%	N20846 001 APR 29, 1998

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

RX	* THERATECH	2.5MG/24HR	N20489 001 SEP 29, 1995
	+	2.5MG/24HR	N20489 001 SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

AB	ESI LEDERLE	250MG	N50278 003
AB	+	500MG	N50278 001
RX	LEDERLE	250MG	N50278 003
RX	*	500MG	N50278 001

TABLET; ORAL
SUMYCIN

	ARCHIMICOM	25MG	N61147 002
		100MG	N61147 004
	@	50MG	N61147 003

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL
SUMYCIN

>ADD>	● APOTHECON	100MG	N61147 002	

>ADD> THALIDOMIDE

>ADD> CAPSULE; ORAL
>ADD> THALOMID
>ADD> + CELGENE 50MG N20785 001
>ADD> JUL 16, 1998

THEOPHYLLINE

CAPSULE; ORAL
ELIXOPHYLLIN

RX	FOREST LABS	100MG	N85545 001 JUL 31, 1984	
RX	*	200MG	N83921 001 JUL 31, 1984	
	●	100MG	N85545 001 JUL 31, 1984	
	●	200MG	N83921 001 JUL 31, 1984	

CAPSULE, EXTENDED RELEASE; ORAL
ELIXOPHYLLIN SR

BC	FOREST LABS	125MG	N86826 001 JAN 29, 1985	
BC		250MG	N86826 002 JAN 29, 1985	>ADD>
	●	125MG	N86826 001 JAN 29, 1985	>ADD>
	●	250MG	N86826 002 JAN 29, 1985	>ADD> >DLT> >DLT> >DLT> >DLT>

TABLET; ORAL
QUIBRON-T

	+ MONARCH PHARMS	300MG	N88656 001 AUG 22, 1985	
	* ROBERTS LABS	300MG	N88656 001 AUG 22, 1985	

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR

BC	KING PHARMS	300MG	N87563 001 JUN 21, 1983	

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
QUIBRON-T/SR

BC	MONARCH PHARMS	300MG	N87563 001 JUN 21, 1983	

THIAMYLAL SODIUM

INJECTABLE; INJECTION
SURITAL

*	PARKE DAVIS	1GM/VIAL	N07600 003
*		5GM/VIAL	N07600 005
*		10GM/VIAL	N07600 009
	● PARKEDALE	1GM/VIAL	N07600 003
	●	5GM/VIAL	N07600 005
	●	10GM/VIAL	N07600 009

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
THIORIDAZINE HCL

AA	PHARM ASSOC	100MG/ML	N40213 001 MAY 29, 1998	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

	● ROCHE	125MG	N19979 001 MAR 24, 1993
	+	250MG	N19979 002 OCT 31, 1991
	● SYNTEX	125MG	N19979 001 MAR 24, 1993
	*	250MG	N19979 002 OCT 31, 1991

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT

	+ MERCK	EQ 0.05MG BASE/ML	N20913 001 MAY 14, 1998

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION
AGGRASTAT
+ MERCK — EQ 0.25MG BASE/ML — N20912 001 MAY 14, 1998

TOLCAPONE

TABLET; ORAL
TASMAR
ROCHE — 100MG — N20697 001 JAN 29, 1998
+ — 200MG — N20697 002 JAN 29, 1998

TOLTERODINE TARTRATE

TABLET; ORAL
DETROL
PHARMACIA AND UPJOHN — 1MG — N20771 001 MAR 25, 1998
+ — 2MG — N20771 002 MAR 25, 1998

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX
[redacted] — 10MG/ML — [redacted]
+ ROCHE — 10MG/ML — N20137 002 AUG 23, 1993

TABLET; ORAL
DEMADEX
[redacted] — 5MG — [redacted]
— 10MG — [redacted]
— 20MG — [redacted]
[redacted] — 100MG — [redacted]
ROCHE — 5MG — N20136 001 AUG 23, 1993

TORSEMIDE

TABLET; ORAL
DEMADEX
ROCHE — 10MG — N20136 002 AUG 23, 1993
— 20MG — N20136 003 AUG 23, 1993
+ — 100MG — N20136 004 AUG 23, 1993

TRETINOIN

CREAM; TOPICAL
AVITA
[redacted] — [redacted] — [redacted]
AB — 0.025% — N20404 003 JAN 14, 1997

GEL; TOPICAL
AVITA
BX PENEDERM — 0.025% — N20400 001 JAN 29, 1998
— [redacted] — [redacted]
RETIN-A
[redacted] — [redacted] — [redacted]
BX + JOHNSON AND JOHNSON — 0.025% — N17579 002

SOLUTION; TOPICAL
RETIN-A
[redacted] — [redacted] — [redacted]
AT + JOHNSON AND JOHNSON — 0.05% — N16921 001
TRETINOIN
AT COPLEY PHARM — 0.05% — N74873 001 JUN 19, 1998

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
@ ALPHARMA — 0.025% — N87797 001 JUN 07, 1982
AT [redacted] — [redacted] — [redacted]

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
AB		EQ 2MG BASE	N87613 001 NOV 19, 1982
AB	[illegible]	[illegible]	[illegible]
AB		[illegible]	[illegible]

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	CIRCA	2MG	N40184 001 FEB 06, 1998
AA		5MG	N40184 002 FEB 06, 1998

TRIMETHAPHAN CAMSYLATE

[illegible]
[illegible]

*	[illegible]	[illegible]	[illegible]
	●	50MG/ML	N08983 001

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

> ADD >	+	US BIOSCIENCE	EQ 200MG BASE/VIAL	N20326 002 JUL 31, 1998
> ADD >				

TROGLITAZONE

TABLET; ORAL
REZULIN

AB	[illegible]	[illegible]	[illegible]
AB		[illegible]	[illegible]

TROGLITAZONE

TABLET; ORAL
REZULIN

AB	[illegible]	[illegible]	[illegible]
AB	PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB		300MG	N20720 003 AUG 04, 1997
AB		400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
TROPICAMIDE

AT	[illegible]	[illegible]	[illegible]
	●	1%	N88447 001 AUG 28, 1985

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR
FERTINEX

	+ SERONO	75 IU/AMP	N19415 002 SEP 18, 1986
	+	150 IU/AMP	N19415 003 SEP 18, 1986
	[illegible]		
	* [illegible]	[illegible]	[illegible]
	*	[illegible]	[illegible]

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

AP	[illegible]	[illegible]	[illegible]
AP		[illegible]	[illegible]
	●	2.5MG/ML	N72233 001 FEB 26, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL
● MARSAM 2.5MG/ML A73485 001
SEP 27, 1993

VIDARABINE

INJECTABLE; INJECTION
VIRA-A
[redacted]
● PARKEDALE EQ 187.4MG BASE/ML N50523 001

OINTMENT; OPHTHALMIC
VIRA-A
[redacted]
✦ PARKEDALE 3% N50486 001

WATER FOR INJECTION, STERILE

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
AP B BRAUN 100% N19633 001
FEB 29, 1988
[redacted]

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL
EXCEDRIN (MIGRAINE)

+	BRISTOL MYERS	250MG;250MG;65MG	N20802 001 JAN 14, 1998

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
GAVISCON

*	[redacted]	[redacted]	[redacted]
		80MG;20MG	N18685 001 DEC 09, 1983
+		160MG;40MG	N18685 002 DEC 09, 1983

GAVISCON-2

*	[redacted]	[redacted]	[redacted]

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
CHG SCRUB

	ECOLAB	4%	N19258 002 JUL 22, 1986
	[redacted]	[redacted]	[redacted]

CIDA-STAT

	ECOLAB	2%	N19258 001 JUL 22, 1986
	[redacted]	[redacted]	[redacted]

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	LEK PHARM	100MG	N75122 001 JUN 19, 1998	>ADD>
		200MG	N75122 002 JUN 19, 1998	>ADD>
	NOVOPHARM	200MG	N74961 001 JUN 19, 1998	>ADD>
				>ADD>
				>ADD>
				>ADD>
				>ADD>

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	PERRIGO	100MG	N74972 001 JUN 19, 1998
	PHARM FORM	200MG	N74963 001 JUN 19, 1998
	TORPHARM	100MG	N74948 001 JUN 19, 1998

CLOTRIMAZOLE

TABLET; VAGINAL
GYNIX

	COPLEY PHARM	100MG	N73249 001 FEB 13, 1998

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S ADVIL-FLAVORED

*	[redacted]	[redacted]	[redacted]
		100MG/5ML	N20589 002 NOV 07, 1997

SUSPENSION/DROPS; ORAL
PEDIATRIC ADVIL

+	WHITEHALL ROBINS	100MG/2.5ML	N20812 001 JAN 30, 1998

TABLET; ORAL
IBUPRIN

	[redacted]	[redacted]	[redacted]
@		200MG	N71773 001 JUL 16, 1987

IBUPROFEN

	NOVOPHARM	200MG	N74931 001 JUL 20, 1998
	PHARM FORM	200MG	N74782 001 JUL 06, 1998

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN

	[redacted]	[redacted]	[redacted]

IBUPROFEN

TABLET, CHEWABLE; ORAL
JUNIOR STRENGTH MOTRIN
+ MCNEIL 100MG N20601 003
NOV 15, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MONISTAT 3
+ ADVANCED CARE PRODS 4% N20827 001
MAR 30, 1998

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
>ADD< NOVEX 2% N74924 001
>ADD< APR 29, 1998
>DLT< [redacted] 2% [redacted]
>DLT< [redacted]

MINOXIDIL (FOR WOMEN)
>ADD< NOVEX 2% N74924 002
>ADD< APR 29, 1998
>DLT< [redacted] 2% [redacted]
>DLT< [redacted]

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
>ADD< PAR PHARM EQ 200MG BASE N75168 001
>ADD< JUL 28, 1998

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTROL
+ [redacted] [redacted] [redacted]
[redacted]
+ PHARMACIA AND UPJOHN 15MG/16HR N20536 001
JUL 03, 1996

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
ZANTAC 75
+ GLAXO WELLCOME EQ 75MG BASE N20745 001
FEB 26, 1998

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JUL '98

NO JULY 1998 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/12/1998
1,5-(Butylimino) -1,5 dideoxy,D-glucitol TN=	Treatment of Gaucher disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington Oxfordshire OX14 3YS UK, DD=05/29/1998
Aldesleukin TN= Proleukin	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville, CA 94608 DD=09/10/1996 MA=01/09/1998
Aldesleukin TN= Proleukin	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville, CA 94608 DD=07/31/1998
Aliperetinate TN= Panretin	For the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Alpha-galactosidase A TN=	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. Cambridge, MA 02139 DD=06/22/1998
Amifostine TN= Ethyol	Reduction of the incidence and severity of radiation-induced xerostomia.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998
Arsenic trioxide TN=	Treatment of acute promyelocytic leukemia.	PolaRx, Inc. 787 7th Ave., 48th Floor New York, NY 10019 DD=03/03/1998
Basiliximab TN= Simulect	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover, NJ 07936 DD=12/12/1997 MA=05/12/1998
Beclomethasone dipropionate TN=	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle, WA 98109 DD=03/27/1998
Benzydamine hydrochloride TN= Tantum	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=05/18/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Bindarit TN=	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge, NJ 07661 DD=02/03/1998
Carbamylglutamic acid TN=	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60 avenue du President Wilson 92046 Paris France, DD=01/20/1998
Corticotropin-releasing factor, human TN= Xerecept	Treatment of peritumoral brain edema.	Neurobiolcgical Technologies, Inc. 1387 Marina Way South Richmond, CA 94804 DD=04/06/1998
Dimethylsulfoxide TN=	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/06/1998
Filgrastim TN= Neupogen	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. 1840 DeHavilland Drive Thousand Oaks, CA 91320 DD=11/07/1996 MA=04/02/1998
Fructose-1,6-diphosphate TN=	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=05/29/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Hydroxyurea TN= Droxia	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton, NJ 08543 DD=10/01/1990 MA=02/25/1998
L-baclofen TN=	Treatment of trigeminal neuralgia.	Pharmascience, Inc. 8400 Darnley Road Montreal, Quebec Canada H4T 1M4, DD=01/06/1998
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Germany DD=02/13/1997 MA=03/06/1998
Liposomal Cyclosporin A TN= Cyclospire	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Molecular Physiology One Baylor Plaza Houston, TX 77030 DD=04/30/1998
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl TN= ImmTher	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff, IL 60044 DD=06/10/1998
Mafenide acetate solution TN= Sulfamylon solution	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown, WV 26504 DD=07/18/1990 MA=06/05/1998
PEGASYS TN=	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=07/13/1998
Pentostatin TN=	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. Two Annbel Lane, Suite 220 San Ramon, CA 94583 DD=03/27/1998
Phenylacetate TN=	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=03/06/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pilocarpine HCl TN= Salagen	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 9900 Bren Road East Suite 300E Minneapolis, MN 55343 DD=02/28/1992 MA=02/11/1998
Prostaglandin E1 enol ester (AS-013) TN=	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Alpha Therapeutic Corp. 5555 Valley Blvd. Los Angeles, CA 90032 DD=06/12/1998
Radiolabeled monoclonal antibody to CD22 antigen on B-cells TN= LymphoCIDE	Treatment of non-Hodgkin's lymphoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=07/13/1998
Recombinant bactericidal/permeability-increasing protein TN= Neuprex	Treatment of severe meningococcal disease.	Xoma Corporation 2910 Seventh Street Berkeley, CA 94710 DD=06/22/1998
Recombinant human Clara Cell 10kDa protein TN=	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park, MD 20742 DD=07/13/1998
Recombinant humanized monclonal antibody 5c8 TN=	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/03/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant humanized monoclonal antibody 5c8 TN=	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=02/18/1998
Rifapentine TN= Priftin	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 H3-M2516 Kansas City, MO 64134 DD=06/09/1995 MA=06/22/1998
Rifaximin TN= Normix	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road Palo Alto, CA 94303 DD=02/10/1998
S-adenosylmethionine TN=	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Dept. of Neurology Philips Building, Suite 2Q; 10 Union Square New York, NY 10003 DD=04/30/1998
Sacrosidase TN= Sucraid	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka, MN 55305 DD=12/10/1993 MA=04/09/1998
Sodium phenylbutyrate TN=	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Targon Corporation 307 College Road East Princeton, NJ 08540 DD=04/24/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
TAK-603 TN=	Treatment of Crohn's disease.	TAP Holdings Inc. 2355 Waukegan Road Deerfield, IL 60015 DD=05/13/1998
Tacrolimus TN= Prograf	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield, IL 60015 DD=04/06/1998
Tetrabenazine TN=	Treatment for moderate/severe tardive dyskinesia.	Lifehealth Limited Richmond House, Old Brewery Court, Sandyford Road Newcastle upon Tyne NE2 1XG England, DD=05/12/1998
Thalidomide TN= Thalomid	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=07/26/1995 MA=07/16/1998
Thalidomide TN=	Treatment of primary brain malignancies.	EntreMed, Inc. 9610 Medical Center Drive, Suite 200 Rockville, MD 20850 DD=02/27/1998
Thalidomide TN=	Treatment of Kaposi's sarcoma.	EntreMed, Inc. 9610 Medical Center Dr., Suite 200 Rockville, MD 20850 DD=07/29/1998
Thymalfasin TN= Zadaxin	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo, CA 94404 DD=01/08/1998

Orphan Product Designations and Approvals List
January 1998 through July 1998

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Tiapride TN=	Treatment of Tourette's syndrome.	Synthelabo Research, Inc. 400 Plaza Drive Secaucus, NJ 07094 DD=04/21/1998
Transgenic human alpha 1 antitrypsin TN=	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland U.K., DD=03/06/1998

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1998 ADDITIONS

PATENT AND EXCLUSIVITY TERMS PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 18TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ABBREVIATIONS

PED	PEDIATRIC EXCLUSIVITY

REFERENCES

NEW DOSING *SCHEDULE*

D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM " ...1/2-1 HOUR BEFORE EATING..." TO "...RIGHT BEFORE EATING OR UP TO 60 MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30 MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICCLIN, FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

NEW INDICATION

I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOICATED WITH ALLERGIC AND NONALLERGIC PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60 MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CISPLATIN, FOR THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

PATENT USE CODE

U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C, BY ADMINISTERING AN AGONIST OF LR-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKISON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGETS DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PRO\ 'LE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3 MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO THE AFFECTED EYE A COMPOSITION COMPRISING A NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482	004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	020802	001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)				NP	JAN 14, 2001
	020059	001	ADENOSINE;ADENOSCAN	5070877	DEC 10, 2008	U-116		
				5731296	MAR 24, 2015	U-221		
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5766573	JUN 16, 2015			
>ADD>	020560	001	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
>ADD>	020560	002	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
>ADD>	020560	003	ALENDRONATE SODIUM;FOSAMAX	5804570	FEB 17, 2015			
	020511	001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U-243		
	019787	001	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	002	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
	019787	003	AMLODIPINE BESYLATE;NORVASC	4572909	JUL 31, 2006			
>ADD>	020304	001	APROTININ BOVINE;TRASYLOL				I-233	AUG 28, 2001
	020420	001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U-220		
				5234404	AUG 10, 2010	U-220		
				5395970	MAR 07, 2012			
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-218	JUL 10, 2001
							I-219	JUL 10, 2001
	020114	001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U-207		
	018521	001	BECLOMETHASONE DIPROPIONATE;VANCENASE	4364923	DEC 21, 1999			
	017573	001	BECLOMETHASONE DIPROPIONATE;VANCERIL	4364923	DEC 21, 1999			
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH	4364923	DEC 21, 1999			
	019408	001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	020816	001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U-224	NCE	APR 01, 2003
				5378703	AUG 31, 2010	U-224		
				5461081	OCT 24, 2012	U-225		
	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5731000	AUG 12, 2013			
>ADD>	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U-177		
	020554	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
	020313	002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U-227		
	020521	001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
	020838	001	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	002	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020838	003	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020838	004	CANDESARTAN CILEXETIL;ATACAND	5196444	APR 18, 2011	U-3	NCE	JUN 04, 2003
				5508297	FEB 24, 2014	U-3		
				5534534	JUL 09, 2013			
				5703110	APR 18, 2011			
				5705517	APR 18, 2011			
	020896	001	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020896	002	CAPECITABINE;XELODA				NCE	APR 30, 2003
	020712	001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020712	002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U-215		
	020297	001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U-3		
				5760069	JUN 07, 2015	U-233		
	020297	004	CARVEDILOL;COREG	5760069	JUN 07, 2015	U-233		
	020774	001	CHLORHEXIDINE GLUCONATE;PERIOCHIP				NP	MAY 15, 2001
	020238	002	CIMETIDINE;TAGAMET HB				D-41	JUN 05, 2001
	020369	001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	JUN 02, 2004	U-223	NDF	MAR 30, 2001
	020805	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003		NC	FEB 10, 2001
				4844902	FEB 11, 2008			
	020780	001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020780	002	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
	020822	002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020822	004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
	020839	001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003			
				4847265	FEB 12, 2008			
				5576328	JAN 31, 2014			
	017922	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	017922	003	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	018938	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013			
	019955	001	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	019955	002	DESMOPRESSIN ACETATE;DDAVP	5763407	DEC 23, 2013		I-40	MAR 25, 2001
	020713	001	DESOGESTREL;MIRCETTE				NP	APR 22, 2001
>ADD>	020344	001	DEXFENFLURAMINE HYDROCHLORIDE;REDUX	4309445	FEB 19, 2004	U-133		
	020809	001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U-239		
				5653972	NOV 16, 2014	U-239		
	020037	001	DICLOFENAC SODIUM;VOLTAREN				I-213	FEB 25, 2001
	020148	001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	4758423	JUL 31, 2001			
				4462983	JUL 31, 2001	U-227		
				5169849	DEC 08, 2009			
						U-227		
	020401	001	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	002	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	003	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020401	004	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020401	005	DILTIAZEM HYDROCHLORIDE;TIAZAC				I-133	JAN 30, 2001
	020449	001	DOCETAXEL;TAXOTERE				I-231	JUN 22, 2001
>ADD>	020690	001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
>ADD>	020690	002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
	020869	001	DORZOLAMIDE HYDROCHLORIDE;COSOPT				NC	APR 07, 2001
	020164	001	ENOXAPARIN SODIUM;LOVENOX				I-217	JAN 30, 2001
							I-222	MAR 27, 2001
	020164	002	ENOXAPARIN SODIUM;LOVENOX				I-222	MAR 27, 2001
							I-217	JAN 30, 2001
	020738	004	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
	020738	005	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3		
>ADD>	020718	001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
>ADD>				5686570	NOV 11, 2014			
>ADD>	020718	002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		NCE	MAY 18, 2003
>ADD>				5686570	NOV 11, 2014			
	020375	003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
	083209	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	086715	001	ESTROGENS, ESTERIFIED;ESTRATAB				I-214	MAR 10, 2001
	020363	001	FAMCICLOVIR;FAMVIR				NCE	JUN 29, 1999
>ADD>							I-232	JUN 12, 2001
>ADD>	020363	002	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
>ADD>	020363	003	FAMCICLOVIR;FAMVIR				I-232	JUN 12, 2001
	020752	001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
	020752	002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
				4305502	DEC 15, 1998			
				4371516	JAN 31, 2000	U-241		
>ADD>	020625	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	4254129	FEB 18, 2001	U-139		
>ADD>	020786	001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	4254129	FEB 18, 2001		NCE	JUL 25, 2001
				5375693	AUG 03, 2012			
				5578610	NOV 26, 2013			
	020788	001	FINASTERIDE;PROPECIA	5547957	OCT 15, 2013	U-236		
	020180	001	FINASTERIDE;PROSCAR				I-221	MAR 20, 2001
	018830	001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018830	004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
	018554	001	FLUTAMIDE;EULEXIN	4472382	SEP 18, 2001	U-24		
				5712251	SEP 18, 2001	U-216		
	020121	001	FLUTICASONE PROPIONATE;FLONASE				I-224	OCT 31, 2000
	020378	001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
	020378	002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242		
				5767251	JUN 16, 2015			
>ADD>	020961	001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE				NCE	AUG 26, 2003
	020450	001	FOSPHENYTOIN SODIUM;CEREBYX	4260769	APR 07, 2003			
>ADD>	019596	001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5560903	OCT 01, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020460	001	GANCICLOVIR;CYTOVENE	4423050	MAY 21, 2001	U-64		
>ADD>				4642346	JUN 24, 2005			
>ADD>				4507305	MAY 12, 2001	U-64		
>ADD>	020509	001	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
>ADD>	020509	002	GEMCITABINE HYDROCHLORIDE;GEMZAR				I-234	AUG 26, 2001
	020695	001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
	020818	001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020818	002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U-3	NCE	DEC 23, 2001
							NC	MAR 06, 2001
	020716	001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U-55		
	016295	002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
	016295	004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
>ADD>	019771	001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	NOV 12, 2002			
>ADD>				4552899*PED	MAY 12, 2003			
>ADD>	019833	002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
>ADD>				4788220*PED	MAY 29, 2006			
>ADD>	020589	001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
>ADD>				4788220*PED	JAN 08, 2008		PED	DEC 16, 1998
>ADD>	020516	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
>ADD>				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
>ADD>	020601	001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
>ADD>				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
>ADD>	020603	001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
>ADD>				5374659*PED	JUN 20, 2012		PED	DEC 16, 1998
>ADD>	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
>ADD>							PED	DEC 16, 1998
>ADD>	020601	003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010		NP	NOV 15, 1999
>ADD>				5215755*PED	DEC 01, 2010		PED	MAY 15, 2000
>ADD>	020602	001	IBUPROFEN;JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
>ADD>							PED	DEC 16, 1998
>ADD>	019842	001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
>ADD>				5374659*PED	JUN 20, 2012			
>ADD>	020135	001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
>ADD>				5320855	JUN 14, 2011			
>ADD>				5215755*PED	DEC 01, 2010			
>ADD>				5320855*PED	DEC 14, 2011			
>ADD>	020135	002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
>ADD>				5320855	JUN 14, 2011			
>ADD>				5215755*PED	DEC 01, 2010			
>ADD>				5320855*PED	DEC 14, 2011			
>ADD>	020812	001	IBUPROFEN;PEDIATRIC ADVIL				NP	JUN 16, 1998
>ADD>							PED	DEC 16, 1998
	020903	001	INTERFERON ALFA-2B;REBETRON	4530901	JUL 23, 2002		NP	JUN 03, 2001
				4211771	JUL 08, 1999	U-234		
				5767097	JAN 23, 2016	U-235		
	020923	001	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002			
	020923	002	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020923	003	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002			
	020393	001	IPRATROPIUM BROMIDE;ATROVENT				I-223	APR 01, 2001
>ADD>	020571	001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
	020657	001	ITRACONAZOLE;SPORANOX	4267179	JUN 23, 2000			
	019927	001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
>ADD>	020241	001	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020241	002	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020241	003	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020241	004	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020241	005	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020241	006	LAMOTRIGINE;LAMICTAL				ODE	AUG 24, 2005
>ADD>	020764	001	LAMOTRIGINE;LAMICTAL CD				ODE	AUG 24, 2005
>ADD>	020764	002	LAMOTRIGINE;LAMICTAL CD				ODE	AUG 24, 2005
>ADD>	020764	003	LAMOTRIGINE;LAMICTAL CD				ODE	AUG 24, 2005
	020406	001	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001
	020406	002	LANSOPRAZOLE;PREVACID				I-227	MAR 12, 2001
							D-42	JUL 20, 2001
	020807	001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
							NCE	MAR 06, 2003
	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020517	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5716640	SEP 02, 2013			
	020263	002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020263	006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5716640	SEP 02, 2013			
	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5716640	SEP 02, 2013			
	020517	002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5716640	SEP 02, 2013			
	019941	001	LIDOCAINE;EMLA				I-215	FEB 04, 2001
	020962	001	LIDOCAINE;EMLA				NP	FEB 04, 2001
	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5716641	MAY 21, 2012	U-226		
	020803	001	LOTEPREDNOL ETABONATE;ALREX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020583	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	020841	001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008		NCE	MAR 09, 2003
				5540930	OCT 25, 2013			
	019832	003	MAFENIDE ACETATE;SULFAMYLON				NDF	JUN 05, 2001
							ODE	JUN 05, 2005
	020652	001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	JUN 12, 2007			
				4992554	FEB 12, 2008			
				5091169	FEB 25, 2009			
				5223243	JUN 29, 2010	U-237		
				4647447	MAR 03, 2004	U-238		
	019618	001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
				RE33239	MAY 12, 2004			
	020208	001	METRONIDAZOLE;METROGEL-VAGINAL				D-40	MAY 16, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020827	001	MICONAZOLE NITRATE;MONISTAT 3				NP	MAR 30, 2001
	020762	001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001			
	020830	001	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020829	002	MONTELUKAST SODIUM;SINGULAR	5565473	NOV 30, 2010	U-228	NCE	FEB 20, 2003
	020763	001	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020763	002	NARATRIPTAN HYDROCHLORIDE;AMERGE				NCE	FEB 10, 2003
	020536	001	NICOTINE;NICOTROL	4915950	FEB 12, 2008			
	020555	001	NIZATIDINE;AXID AR				I-220	APR 01, 2001
							D-39	APR 01, 2001
	020799	001	OFLOXACIN;FLOXIN				NDF	DEC 16, 2000
>ADD>	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	DEC 18, 2010			
	019810	001	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	019810	002	OMEPRAZOLE;PRILOSEC				I-229	JUN 29, 2001
	020262	001	PACLITAXEL;TAXOL				I-226	APR 09, 2001
							I-230	JUN 30, 2001
	020819	001	PARICALCITOL;ZEMPLAR				NCE	APR 17, 2003
>ADD>	020710	001	PAROXETINE HYDROCHLORIDE;PAXIL	5811436	SEP 22, 2015			
	020237	001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
							I-212	FEB 11, 2001
	020667	001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	020667	005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	DEC 12, 2006			
				4843086	JUN 27, 2006	U-231		
	019898	002	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	003	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019898	004	PRAVASTATIN SODIUM;PRAVACHOL				I-225	MAR 27, 2001
	019781	001	PROGESTERONE;PROMETRIUM				NP	MAY 14, 2001
	019627	002	PROPOFOL;DIPRIVAN	5731355	MAR 22, 2015	U-217		
				5731356	MAR 22, 2015	U-218		
	020815	001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2001			
				5393763	JUL 28, 2012	U-114		
				5457117	JUL 28, 2012	U-114		
				5478847	MAR 02, 2014	U-114		
	020520	001	RANITIDINE HYDROCHLORIDE;ZANTAC 75				I-228	JUN 08, 2001
	021024	001	RIFAPENTINE;PRIFTIN				NCE	JUN 22, 2003
							ODE	JUN 22, 2005
	020835	001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	NCE	MAR 27, 2003
	020272	005	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009		D-37	OCT 17, 2000
>ADD>	020864	001	RIZATRIPTAN BENZOATE;MAXALT	5602162	MAY 10, 2015	U-240	NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
>ADD>	020864	002	RIZATRIPTAN BENZOATE;MAXALT	5602162	MAY 10, 2015	U-240	NCE	JUN 29, 2003
				5298520	JAN 28, 2012	U-240		
>ADD>	020865	001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	MAY 10, 2015	U-240	NCE	JUN 29, 2003
				4305502	DEC 15, 1998			
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020865	002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5602162	MAY 10, 2015	U-240	NCE	JUN 29, 2003
				4305502	DEC 15, 1998			
				5298520	JAN 28, 2012	U-240		
				4758598	DEC 15, 1998			
				4371516	FEB 01, 2000			
>ADD>	020533	001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
>ADD>	020533	003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
>ADD>	020533	004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
>ADD>	020533	005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	JUL 28, 2010			
	020772	001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
							NCE	APR 09, 2003
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5126375	FEB 12, 2008		I-216	FEB 05, 2001
	020692	001	SALMETEROL XINAFOATE;SEREVENT	5225445	FEB 12, 2008	U-211		
				5380922	JAN 10, 2012			
				5590645	MAR 01, 2011			
				5126375	FEB 12, 2008			
				D342994	JAN 04, 2008			
>ADD>	020828	001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2012			
	020443	001	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020443	002	SERMORELIN ACETATE;GEREF	4517181	MAY 14, 2002			
				4703035	DEC 28, 2004			
	020895	001	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	002	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	020895	003	SILDENAFIL CITRATE;VIAGRA	5250534	JUN 18, 2011		NCE	MAR 27, 2003
	019676	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	019676	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	OCT 29, 2004
	020181	001	SOYBEAN OIL;LIPOSYN III 30%				NP	JAN 13, 2001
	020626	001	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	002	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020626	003	SUMATRIPTAN;IMITREX	5037845	AUG 06, 2008			
				5307953	DEC 02, 2012			
				5554639	SEP 10, 2013	U-232		
				5705520	DEC 10, 2011	U-232		
	020791	001	TESTOSTERONE;TESTODERM	4379454	FEB 17, 2001			
	020785	001	THALIDOMIDE;THALOMID				NCE	JUL 16, 2003
							ODE	JUL 16, 2005
	020912	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			
	020913	001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAR 08, 2011	U-230	NCE	MAY 14, 2003
				5658929	MAR 08, 2011			
				5733919	OCT 23, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020697	001	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020697	002	TOLCAPONE;TASMAR	5236952	AUG 17, 2010		NCE	JAN 29, 2003
				5476875	DEC 19, 2012	U-219		
	020771	001	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
	020771	002	TOLTERODINE TARTRATE;DETROL	5382600	JAN 17, 2012		NCE	MAR 25, 2003
>ADD>	020671	001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
	020137	002	TORSEMIDE;DEMADEX				D-38	FEB 13, 2001
	020528	001	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	002	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
	020528	003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U-229		
>ADD>	020719	001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
>ADD>	020719	002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
>ADD>	020719	003	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
>ADD>	020720	001	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
>ADD>	020720	002	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
>ADD>	020720	003	TROGLITAZONE;REZULIN	4572912	NOV 09, 2008			
	020675	001	URSODIOL;URSO	4859660	AUG 22, 2006			
	020699	001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020699	004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007			
	020388	001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
>ADD>	020471	001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		
>ADD>	020471	003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U-168		

Government Printing Office: 1998 — 454-723/00001

New 19th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
*** 8240**

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $78.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account _____ – __
☐ VISA or MasterCard

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

( )
_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.


UNITED STATES OF AMERICA
GOVERNMENT PRINTING OFFICE
1.0
1.1
1.25
1.4
1.6
2.8
2.5
3.2
2.2
3.6
2.0
1.8
6"